   
 1  A Phase II Study of Capecitabine, Temozolomide and Bevacizumab for Metastatic 
or Unresectable Pancreatic Neuroendocrine Tumors  
 
 
NCT0152508 2 
Version 1 2.0 / 0 7.25.14 
 
 
 
Coordinating Center:   Stanford Cancer Institute    
     [ADDRESS_54609], CA [ZIP_CODE]  
 
Principal Investigator :  [INVESTIGATOR_51671] L. Kunz, MD  
     Stanford University School of Medicine  
  Department of Medicine / Division of Oncology  
     [ADDRESS_54610], CA [ZIP_CODE] -5826  
Phone : xxx-xxx-xxxx 
     Fax: xxx-xxx-xxxx 
     [EMAIL_971]  
 
Co-Investigators:    George A. Fisher, MD, PhD  
  Stanford University School of Medicine  
  Department of Medicine / Division of Oncology  
     [ADDRESS_54611] Uni versity School of Medicine  
  Department of Medicine / Division of Oncology  
  [ADDRESS_54612];  
Stanford, CA [ZIP_CODE] -5105 
 
Statistician:   Alex McMill an, PhD  
  Stanford University  School of Medicine  
Biostatistics, Health Research and Policy  
[ADDRESS_54613],  
Stanfor d, CA [ZIP_CODE] -5405  
 
Pharmacists :  Martha Hamilton, Pharm D  
  Stanford University  School of Medicine  
  [ADDRESS_54614], CA, [ZIP_CODE]  
  Phone: (xxx)-xxx-xxxxx  
  Fax: (xxx)-xxx-xxxx 
   
  
Research Pharmacist  
H. Lee Moffitt Cancer Center  
[EMAIL_972]   
 
Research Coordinator s:  Prachi Nandoskar   
  Stanford Cancer Center  
  [ADDRESS_54615], CA [ZIP_CODE]  
   
   
 
Research Coordinator  
H. Lee Moffitt Cancer Center  
Tampa, FL [ZIP_CODE]  
   
 
Protocol Version/Date:   Version 1 2.0 / 0 7.25.14 
 
Revision history:    Version 10.0 / 09.07.12  
Version 9.0 / 10.20.11  
                                                      Version 8.0 / 10.06 .11 
Version 8.0 / 9.29.11 
Version 7.0 / 9.25.11 
Versio n 6.0 / 9.6.11 
Version 5.0 / 8.7.11 
Version 4.0 / 7.27.11 
   
 3 Version 3.0 / 6.13.11 
Version 2.0 / 5.10.11  
Version 2.0 / 4.7.11  
   
 4 Protocol Synopsis  
 
A Phase II Study of Capecitabine, Temozolomide and Bevacizumab for 
Metastatic or Unresectable Pancreatic Neuroen docrine Tumors  
 
 
Principal Investigator:  [INVESTIGATOR_51671] L. Kunz, MD  
    Assistant Professor of Medicine  
 Stanford University Cancer Center  
    [ADDRESS_54616], CA [ZIP_CODE] -5826  
    Phone:  
    Fax:  
    [EMAIL_971]  
 
 
Study Centers : Stanford University School of Medicine  (coordinating institution ), , H. 
Lee Moffitt Cancer Center  (subsite)  
 
Number of subjects planned:  30 ([ADDRESS_54617] and 10 at Moffitt ) 
 
Planned accrual:  
• 2-4 patients per month per  site with enrollment complete in 18 months . 
• Time on study per patient estimated at 6-9 months.  
• Median follow -up at time of study completion estimated at 12 months.  
Objectives  
1. Primary Objective  
a. To estimate the Radiographic Response Rate  (RR), as defined by  [CONTACT_51708] 1.1 , under  the combination of capecitabine and temozolomide with 
bevacizumab in patients with  metastatic or unresectable pancreatic 
neuroendocrine tumors in comparison with the  historical control  rate. 
b. To assess the toxicities using CTCAE v 4.0. 
 
2. Secondary Objectives  
a. To evaluate progression -free survival (PFS) and overall survival (OS) using 
Kaplan -Meier analysis  
b. To assess MGMT by [CONTACT_51709]  
c. To assess serum hormone marker levels  
d. To evaluate CT Perfusion as a tool to predict early the rapeutic response  
(OPTIONAL ) 
e. To bank serum for future correlative analyses  
   
 [ADDRESS_54618] scans at baseline and after every 
3 cycles (approximately 3 months) and be evaluated by [CONTACT_13407].  We estimate 
that most patients will complete 6 -9 cycles of treatment.  Dose reductions are allowed 
after cycle 1. If, after 3 cycles, patients develop significant toxicities attributed to either 
temozolomide ( including nausea, cytopenias , etc) or capecitabine  (including diarrhea, 
hand -foot skin syndrome , etc ) patients may discontinue these agent s and continue 
receiving bevacizumab as a single agent.  We will continue treatment indefinitely until one 
of the following occurs: patient withdraws consent and decide s to discontinue study 
treatment, development of unacceptable toxicities, or evidence fo r progression of 
disease.  If a patient is on single -agent b evacizumab at the time of disease progression, 
temozolomide and capecitabine may be restarted at the discreti on of the investigator.  
 
 
Target Subject Population  
Patients with unresectable or metast atic pancreatic neuroendocrine tumors will be eligible 
for enrollment in this study. Patients must have measurable disease at the time of 
enrollment. No prior bevaci zumab, fluoropyrimidine (capecitabine or 5FU)  or 
temozolomide will be allowed. Prior suniti nib and everolimus will be allowed.  Tumor 
tissue for MGMT analysis will be requested  for centralized path review  at Stanford  
(archival tissue is acceptable).  
 
Inves tigational Product s, Dosage and Mode of Administration  
Bevacizumab :  10 mg/kg IV days 1 and 15 (28 -day cycle)  
Capecitabine:  750 mg/m2 PO BID days 1 -14 
Temozolomide:  200 mg/ m2 PO QHS  days  10-14 
 
Comparator, Dosage and Mode of Administration  
None.  
 Bevacizumab 10  mg/kg IV day 1 and 15  
Capecitabine 750 mg/m2 po BID days 1 -14 
Temozolomide 200 mg/m2 po Q HS days 10 -14 
Repeat Q28 days with imaging Q3 cycles  R
E
G
I
S
T
E
R Screening 
evaluation  Continue until 
disease 
progression  
   
 6 Duration  of Treatment  
Each cycle lasts 28 days.  Patients will continue on treatment until one of the following 
occurs:  
1. Patient chooses to withdraw from study  
2. Unacceptable toxicity occurs  
3. Evidence of progressive disease by [CONTACT_13407]  
4. At the discr etion of the investigator  
 
Safety  
Safety assessments will consist o f routine and frequent monitoring and recording of all 
adverse events and serious adverse events, regular monitoring of hematology and serum 
chemistry, coagulation tests, urinalysis, regula r measurement of vital signs, weight, WHO 
Performance Status and th e performance of physical examination.  The toxicities 
experienced by [CONTACT_51710], and the study’s overall progress, will be 
reviewed weekly at the Stanford University GI Onco logy Research  Meeting . Dose 
adjustments will be made at the discret ion of the investigators as per protocol.  
 
Statistical Methods  
A sample size of 30 patients would give 80% power to reject the null RR of 40% if the true 
response rate ( RR) is 65% or higher . The null hypothesis is based on a prospective phase 
II study conducted by [CONTACT_51711], et al evaluating the efficacy of temozolomide and 
thalidomide1.  In this study, 29  patients with mixed metastatic NETs were treated with 
temozolomide 150 mg/m2 for 7 days every other week and thalidomide at doses of 50 -
400 mg daily.  The overall radiogra phic response was 25% (45% in patients with 
pancreatic NETs).  The alternative hypot hesis is based on the more recent retrospective 
study in patients with pancreatic NETs reported by [CONTACT_51712], et al in which 30 patients 
were treated with capecitabine (750mg/m2 twice daily, days 1 -14) and temozolomide (200 
mg/m2 once daily, days 10 -14) ev ery 28 days ; the RR was 70% .2  RR is defined as the 
proportion of patients with complete respo nse + partial response (CR+PR) based on a 
patient’s best response.  Progression -free survival (PFS) and overall survival (OS) will be 
evaluated using Kaplan -Meier analysis.   For PFS analyses, p atients will be ce nsored at 
time last known alive if no progress ion has occurred.  
  
   
 [ADDRESS_54619] of abbreviations and definition of terms  ................................ ................................ .........  10 
1.0 Background  ................................ ................................ ................................ ..............................  12 
1.1 Disease Background  ................................ ................................ ................................ ....................  12 
1.2 Bevacizumab Clinical Experience  ................................ ................................ ..........................  12 
1.2.1  Safety Profile  ................................ ................................ ................................ ................................ .................  13 
1.3 Temozolom ide Clinical Experience ................................ ................................ ........................  19 
1.3.1  Clinical Pharmacokinetics of Temozolomide ................................ ................................ ...................  19 
1.3.2  Adverse Reactions:  ................................ ................................ ................................ ................................  22 
1.3.3  MGMT Methy lation Status  ................................ ................................ ................................ .......................  23 
1.4 Capecitabine Clinical Experience  ................................ ................................ ...........................  23 
1.4.1 Capecitabin e Safety Profile  ................................ ................................ ................................ ..........................  23 
1.5 Study Rationale  ................................ ................................ ................................ ..............................  24 
1.6 Correlative Studies Background  ................................ ................................ .............................  24 
2.0 Objectives  ................................ ................................ ................................ ................................ .. 27 
3.0 Study Desi gn ................................ ................................ ................................ ............................  27 
3.1 Description of the Study  ................................ ................................ ................................ .............  27 
3.2 Rationale for Study Design ................................ ................................ ................................ ........  28 
3.3 Outcome Measures  ................................ ................................ ................................ .......................  28 
3.3.1  Primary  ................................ ................................ ................................ ................................ ............................  28 
3.3.2  Secondary  ................................ ................................ ................................ ................................ ...........................  28 
3.3.3  Safety  Outcome Measures  ................................ ................................ ................................ ........................  28 
4.0 Safety Plan  ................................ ................................ ................................ ................................  29 
4.1 Bevacizumab -specific  ................................ ................................ ................................ ..................  29 
4.2 Other Study Drug(s) -Specific  ................................ ................................ ................................ ... 30 
5.0 Study Subjects  ................................ ................................ ................................ .........................  30 
5.1 Inclusion Criteria  ................................ ................................ ................................ ............................  30 
5.2 Exclusion Criteria  ................................ ................................ ................................ ..........................  31 
6.0 Study Medications  ................................ ................................ ................................ ..................  33 
6.1  Bevacizumab administration, storage, and toxicity management  ...........................  33 
6.1.1  Bevacizumab Administration  ................................ ................................ ................................ .................  33 
6.1.2  Bevacizumab Storage  ................................ ................................ ................................ ................................  34 
6.1.3  Bevacizumab Dose Modification and Toxicity Management  ................................ .....................  34 
6.2 Temozolomide  administration, storage, and toxicity management  ........................  39 
6.2.1  Temozolomide Administration:  ................................ ................................ ................................ ............  39 
6.2.2 Temozolomide Storage:  ................................ ................................ ................................ ................................ . 40 
6.2.3  Temozolomide Dose Modifications:  ................................ ................................ ...............................  [ADDRESS_54620] -Treatment Evaluations  ................................ ................................ ................................ ...... 48 
7.4 Correlative Tissue/Blood Studies  ................................ ................................ ...........................  [ADDRESS_54621] Discontinuation  ................................ ................................ ................................ ....... 51 
9.0 Study Follow Up  ................................ ................................ ................................ ......................  52 
10.0  Statistical Methods  ................................ ................................ ................................ ................  52 
10.1  Determination of Sample size  ................................ ................................ ................................ .. 52 
10.2  Planned Efficacy Evaluations  ................................ ................................ ................................ ... 53 
11.0  Safety  Reporting of Adverse Events  ................................ ................................ .................  57 
    11.1  Genentech -specific Safety Reporting (for both capecitabine and 
bevacizumab ) ................................ ................................ ................................ ................................ ....... 57 
Assessmen t of Safety  ................................ ................................ ................................ ................................ . 57 
Specification of Safety Variables  ................................ ................................ ................................ ...........................  57 
Adverse Events ................................ ................................ ................................ ................................ .............................  57 
Serious Adverse Events  ................................ ................................ ................................ ................................ ............  58 
Method s and Timing for Assessing AND Recording Safety variables  ................................ .. 58 
Adverse Event Reporting Period  ................................ ................................ ................................ ..........................  58 
Assessment of Adverse Events  ................................ ................................ ................................ ..............................  58 
Procedures for Eliciting, Recording, and Reporting Adverse Events  ................................ ... 59 
Eliciting Adverse Events ................................ ................................ ................................ ................................ ...........  59 
Specific Instructions for Recording Adverse Events  ................................ ................................ ....................  59 
MedWatch 3500A  Reporting Guidelines  ................................ ................................ ................................ ...........  61 
Additional Reporting Requirements for IND Holders  ................................ ................................ .................  62 
IND Annual Reports  ................................ ................................ ................................ ................................ ...................  63 
Study Close -Out  ................................ ................................ ................................ ................................ ............  64 
11.2  Me rck Safety Reporting ................................ ................................ ................................ ...................  64 
12.0  Retention of Records ................................ ................................ ................................ .............  64 
13.0  Data and Safety Monitoring Plan  ................................ ................................ ......................  65 
14.0  Ethical and Regulatory Considerations  ................................ ................................ ..........  66 
SAFETY REPORTING FAX COVER SHEET  ................................ ................................ .....................  74 
 
 
APPENDICES :  
Appendix A: NCI Common Toxicity Criteria , v4.0  (website  provided ) 
Appendix B: FDA MedWatch 3500a Form  (website  provided ) 
Appendix C: NYHA Guidelines  (included)  
Appendix D:  Genentech Safety Reporting Cover Sheet (included)  
 
 
   
 9 ATTACHMENTS:  
Attachment  1:  Informed Consent  Form (separate attachment ) 
 
 
 
   
 [ADDRESS_54622] OF ABBREVIATION S AND DEFINITION OF TERMS  
ADL Activities of daily living  
AE Adverse event  
ALT/SGPT  Alanine transaminase/S erum glutamate pyruvate transaminase  
ANC  Absolute neutrophil count  
AST/SGOT  Aspartate transaminase/Serum glutamic oxaloacetic transaminase  
BID Twice daily  
BSA Body surface area  
CBC  Complete Blood Count  
CI Confidence interval  
Cmax Maximum concentrati on of drug  
CNS  Central Nervous System  
CRC  Colorectal cancer  
CRF Case Report/Record Form  
CR Complete response  
CrCl Creatinine Clearance  
CTCAE  Common Terminology Criteria for Adverse Events  
DLT Dose Limiting Toxicity  
DSMC  Data and Safety Monitoring Committee  
ECG  Electrocardiogram  
EGFR  Epi[INVESTIGATOR_3506]  
5-FU 5-Fluorouracil  
G-CSF Granulocyte colony -stimulating factor (filgrastim)  
GI Gastrointestinal  
Hgb Hemoglobin  
HIV Human Immunodeficiency Virus  
HPF High-power field  
HTN Hyperte nsion  
IRB Institutional Review Board  
IV Intravenous(ly)  
LLN Lower limit of normal  
MGMT  O6-alkyl guanine -DNA alkyltransferase  
NSCLC  Non-small cell lung cancer  
OS Overall survival  
PLT Platelet  
PO Per os/by [CONTACT_1966]/orally  
   
 [ADDRESS_54623] Upper Limit of Normal  
UNK  Unknown  
VEGF  Vascular Endothelial Growth Factor  
VEGF -R Vascular Endothelial Growth Factor Receptor  
WBC  White Blood Cell  
WHO  World Health Organization  
   
 12 1.0 Background  
1.1 Disease Background  
Neuroendocr ine tumors (NETs) are a diverse group of malignancies that range from the 
well-differentiated carcinoid tumor to the poorly or undifferentiated  neuroendocrine 
carcinoma.  While localized disease may potentially be cured with surgical resection, 
systemic th erapi[INVESTIGATOR_51672].   
 
Until recently there has been a paucity of randomized clinical trials using systemic 
therapi[INVESTIGATOR_51673].  However, two recent practice -changing studies have 
validated t he use of new medications for this disease.  The RADIANT -[ADDRESS_54624] single -agent efficacy for advanced NETs5 but even more 
encouraging results when combined with capecitabine with reported response rates of 
70% for pan creatic NETs6.  MGMT deficiency is thought to be predictive of response to 
temozolomide and is more often associated with pancreatic NETs7. 
 
Additionally, NETs  are highly vascular and have been shown to express high levels of 
vascular endothelial growth factor (VEGF).  One of the first studies to incorporate an 
antiangiogenic strategy in this dise ase was a Phase II study using temozolomide and 
thalidomide in met astatic NETs that reported radiographic response rates of 25% (45% 
among pancreatic NETs, 33% among pheochromocytomas and 7% among carcinoid 
tumors .1 A Phase II stud y using temozolomide and bevacizumab for metastatic 
carcinoid and pancreatic NETs also showed activity , with partial responses in 14% of all 
patients and stable disease in 79%8.  Other data suggest th at single -agent 
administration of bevacizumab for advanced carcinoid tumors results in inhibition of 
tumor blood flow and increases progression -free survival9.   
 
These prior studies have demonstrated encouraging results and acceptable toxicity 
profiles.  We propose a multi -institution, phase II, single -arm, non -randomized study 
investigating bevacizumab in combination with temozolomide and capecitabine for 
patients wi th unresectable or metastatic  neuroendocrine tumors.  
 
1.2 Bevacizumab Clinical  Experience    
Bevacizumab has been studied in a multitude of Phase I, II, and III clinical trials in more 
than 5000 patients and in multiple tumor types. In addition, data are av ailable from 3,863 
patients enrolled in two postmarketing studies in metastatic colorectal cancer (CRC).  
   
 [ADDRESS_54625] or  in clinical trials.  The following discussion summarizes beva cizumab’s safety 
profile and presents some of the efficacy results pertinent to this particular trial. Please 
refer to the bevacizumab Investigator Brochure for descriptions of all completed Pha se I, 
II, and III trials reported to date.  
In a large phase II I study (AVF2107g) in patients with metastatic colorectal cancer, the 
addition of bevacizumab, a monoclonal antibody directed against vascular endothelial 
growth factor (VEGF), to irinotecan/5 -fluorouracil/leucovorin (IFL) chemotherapy resulted 
in a clinic ally and statistically significant increase in duration of survival, with a hazard 
ratio of death of 0.67 (median survival 15.6 vs. 20.3  months; p  < 0.001).  Similar increases 
were seen in progr ession -free survival (6.2 vs. 10.6 months; p  < 0.001), overall  response 
rate (35% vs. 45%; p  < 0.01) and duration of response (7.1  vs. 10.4 months; p  < 0.01) for 
the combination arm versus the chemotherapy only arm (bevacizumab Investigator 
Brochure, Octob er 2005).  
Based on the survival advantage demonstrated in Stud y AVF2107g, bevacizumab was 
designated for priority review and was approved on [ADDRESS_54626] -line treatment in combination with IV 5 -FU−based chemotherapy for s ubjects with 
metastatic colorectal cancer.  
Additional data fr om Phase III trials in metastatic CRC (E3200), non −small cell lung 
cancer (NSCLC; E4599), and metastatic breast cancer (E2100) have also demonstrated 
clinical benefit from bevacizumab when added  to chemotherapy.  In Study E3200, the 
addition of bevacizumab  to FOLFOX chemotherapy resulted in improved overall survival 
compared with FOLFOX alone (13.0 vs. 10.8  months, respectively, HR  = 0.75; p   0.01) 
in a population of previously treated CRC patie nts.   
There was also improved overall survival in first -line NSCLC patients (E4599) treated 
with carboplatin/paclitaxel  + bevacizumab compared with chemotherapy alone (12.3 vs. 
10.3 months, respectively; HR  = 0.80; p  = 0.003).  The results from this trial were the 
basis for FDA approval of bevacizumab for use in com bination with 
carboplatin  + paclitaxel as first -line treatment of patients with unresectable, locally 
advanced, recurrent or metastatic, non -squamous NSCLC in October 2006.  Finally, 
patien ts with untreated metastatic breast cancer (E2100) who received bev acizumab in 
combination with weekly paclitaxel had a marked improvement in PFS compared with 
chemotherapy alone (13.3 vs. 6.7  months, respectively; HR  = 0.48; p   0.0001) (see the 
Bevacizum ab Investigator Brochure for additional details).  
1.2.1  Safety Prof ile 
In the initial Phase I and II clinical trials, four potential bevacizumab -associated safety 
signals were identified: hypertension, proteinuria, thromboembolic events, and 
hemorrhage.  A dditional completed Phase II and Phase III studies of bevacizumab a s well 
as spontaneous reports have further defined the safety profile of this agent. 
Bevacizumab -associated adverse events identified in phase III trials include congestive 
heart failure (C HF) primarily in metastatic breast cancer, gastrointestinal perfora tions, 
wound healing complications, and arterial thromboembolic events (ATE). These and other 
   
 14 safety signals are described in further detail as follows and in the bevacizumab 
Investigator B rochure.  
Hypertension : An increased incidence of hypertension has b een observed in patients 
treated with bevacizumab.  Grade [ADDRESS_54627] included hypertensive crisis, hypertensiv e 
encephalopathy, and reversible posterior leukoencephalopathy synd rome (RPLS) 
(Ozcan et al., 2006; Glusker et al., 2006).  
There is no information on the effect of bevacizumab in patients with uncontrolled 
hypertension at the time of initiating bevacizuma b therapy.  Therefore, caution should 
be exercised before initiatin g bevacizumab therapy in these patients.  Monitoring of 
blood pressure is recommended during bevacizumab therapy.  Optimal co ntrol of blood 
pressure according to standard public health guid elines is recommended for patients on 
treatment with or without bev acizumab.   
Temporary interruption of bevacizumab therapy is recommended in patients with 
hypertension requiring medical therapy until adequate control is achieved.  
If hypertension cannot be controlled with medical therapy, bevacizumab therapy should 
be permanently discontinued.  Bevacizumab should be permanently discontinued in 
patients who develop hypertensive crisis or hypertensive encephalopathy.  
Proteinuria :  An increased incidence of proteinuria has been observed in patients treated 
with bevacizumab compared with control arm patients.  In the bevacizumab -containing 
treatment arms of clinical trials (across all indications), the incidence of proteinuria 
(reported as an adverse event) wa s up to 38% (metastatic CRC Study  AVF2192g).  The 
severity of protei nuria has ranged from asymptomatic and transient events detected on 
routine dipstick urinalysis to nephrotic syndrome; the majority of proteinuria events have 
been grade 1. NCI-CTC Grade 3 proteinuria was reported in up to 3% of bevacizumab -
treated patient s, and Grade  4 in up to 1.4% of bevacizumab -treated patients.  The 
proteinuria seen in bevacizumab clinical trials was not associated with renal impairment 
and rarely required permanent dis continuation of bevacizumab therapy.  Bevacizumab 
should be discont inued in patients who develop Grade 4 proteinuria (nephrotic 
syndrome).  
Patients with a history of hypertension may be at increased risk for the development of 
proteinuria when treated with  bevacizumab.  There is evidence from the dose -finding, 
Phase II tr ials (AVF0780g, AVF0809s, and AVF0757g) suggesting that Grade [ADDRESS_54628] every 4 weeks.   
Thromboembolic Events : Both venous and arterial thromboembolic (T E) events, 
ranging in severity from catheter -associated phlebitis to fatal, have been reported in 
patients treated with bevacizumab in the colorectal cancer trials and, to a lesser extent, 
in patients treated with bevacizumab in NSCLC and breast cancer tri als.  
Venous thromboembolism (including deep venous thrombosis, pulmonary 
embolism, and thrombophlebitis :  In the phase III pi[INVESTIGATOR_47273], there 
   
 15 was a slightly hig her rate of venous TE events in patients treated with bevacizumab plus 
chem otherapy compared with chemotherapy alone (19% vs. 16%).  
In Study AVF2107g, a Phase III, pi[INVESTIGATOR_47273], VTE events, including 
deep venous thrombosis, pulmonary embolism, and thrombophlebitis, occurred in 
15.2% of patients receiving chemo therapy alone and 16.6% of patients receiving 
chemotherapy  + bevacizumab.  
The incidence of NCI -CTC Grade   3 venous VTE events in one NSCLC trial (E4599) 
was higher in the bevacizumab -containing arm compared to the chemotherapy control 
arm (5.6% vs. 3.2%) .  One event (0.2%) was fatal in the bevacizumab -containing arm; 
not fatal events were reported in the carboplatin/paclitaxel arm (see Bevacizumab 
Investigator Brochure ).  In metastatic CRC clinical trials, the incidence of VTE events 
was similar in patien ts receiving chemotherapy  + bevacizumab and those receiving the 
control chemotherapy alone.  
In clinical trials across all indications the overall incidence of VTE event s was 
2.8%−17.3% in the bevacizumab -containing arms compared with 3.2% −15.6% in the 
chemotherapy control arms.  The use of bevacizumab with chemotherapy does not 
substantially increase the risk of VTE event compared with chemotherapy alone.  
However, patie nts with metastatic CRC who receive bevacizumab and experienced a 
VTE event may be at h igher risk for recurrence of VTE event.  
Arterial Thromboembolic  Events:  An increased incidence of ATE events was observed 
in patients treated with bevacizumab compar ed with those receiving control treatment.  
ATE events include cerebrovascular accidents, myocardial infarction, transient ischemic 
attacks (TIAs), and other ATE events.  In a pooled analysis of data from five randomized 
Phase II and III trials (mCRC [AVF2107g, AVF2192g, AVF0780g]; locally advanced or 
metastatic NSCLC [AVF0757g]; metastatic bre ast cancer [AVF2119g]), the incidence rate 
of ATE events was 3.8% (37 of 963) in patients who received 
chemotherapy  + bevacizumab compared with 1.7%  (13 of 782) in patients treated with 
chemotherapy alone.  ATE events led to a fatal outcome in 0.8% (8 of 9 63) of patients 
treated with chemotherapy  + bevacizumab and 0.5% (4 of 782) of patients treated with 
chemotherapy alone.  Cerebrovascular accidents (including TIAs) occurred in 2.3% of 
patients treated with chemotherapy  + bevacizumab and 0.5% of patients t reated with 
chemotherapy alone.  Myocardial infarction occurred in 1.4% of patients treated with 
chemotherapy  + bevacizumab compared with 0.7% of pa tients treated with 
chemotherapy alone (see the Bevacizumab Investigator Brochure for additional details).  
Aspi[INVESTIGATOR_33930] a standard therapy for primary and secondary prophylaxis of arterial 
thromboembolic events in patients at high risk of such events, and th e use of aspi[INVESTIGATOR_248] ≤ 
[ADDRESS_54629] to metastatic colorectal cancer patients were 
presented at ASCO 2005 (Hambleton et al., 2005). Further analyses o f the effects of 
concomitant use of bevacizumab and aspi[INVESTIGATOR_51674].  
Gastrointestinal perforation  Patients with metastatic carcinoma may be at increased 
risk for the development of gastrointestinal perforation and fi stula when treated with 
bevacizumab and chemotherapy. Bevacizumab should be permanently discontinued in 
patients who develop gastrointestinal perforation. A causal association of intra -abdominal 
inflammatory processes and gastrointestinal perforation to be vacizumab treatment has 
not been established. Nevertheless, caution should be exercised when treating patients 
with intra -abdominal inflammatory processes with bevacizumab. Gastrointestinal 
perforation has been reported in other trials in non -colorectal ca ncer populations (e.g., 
ovarian, renal cell, pancreas, breast, and NSCLC) and may be higher in incidence in 
some tumor types.  
Fistula :  Bevacizumab use has been associated with serious cases of fistulae including 
events resulting in death.  Fistulae in the  GI tract are common (1% –10% incidence) in 
patients with metastatic CRC, but uncommon (0.1% −1%) or rare (0.01% –0.1%) in other 
indications.  In addition, fistulae that involve areas of the body other than the GI tract 
(e.g., tracheoesophageal, bronchopleura l, urogenital, biliary) have been reported 
uncommonly (0.1% –1%) in patients receiving bevacizumab in clinical studies and 
postmarketing reports.  Events were reported at various timepoints during treatment, 
ranging from 1  week to  [ADDRESS_54630], discontinuation of bevacizumab should be considered.  
Wound healing complications:  Wound -healing complications such as wound 
dehiscence have been reported in pati ents receiving bevacizumab. In an analysis of 
pooled data from two trials in metastatic colorectal cancer, patients undergoing surgery 
28-60 days before study treatment with 5 -FU/LV plus bevacizumab did not appear to have 
an increased risk of wound healing  complications compared to those treated with 
chemotherapy alone (Scappaticci et al., 2005). Surgery in patients currently receiving 
bevacizumab is not recommended. No definitive data are available to define a safe 
interval after bevacizumab exposure with respect to wound healing risk in patients 
receiving elective surgery; however, the estimated half life of bevacizumab is 21 days. 
Bevacizumab should be discontinued in patients with severe wound healing 
complications.  
If patients receiving treatment with b evacizumab require elective major surgery, it is 
recommended that bevacizumab be held for 4 –8 weeks prior to the surgical procedure.  
Patients undergoing a major surgical procedure should not begin or restart 
bevacizumab until 4 weeks after that procedure (in the case of high -risk procedures 
such as liver resection, thoracotomy, or neurosurgery, it is recommended that 
   
 17 chemotherapy be restarted no earlier than 6 weeks and bevacizumab no earlier than 8 
weeks after surgery).  
Hemorrhage : Overall, grade 3 and 4 bleeding events were observed in 4.0% of 1132 
patients treated with bevacizumab in a pooled database from eight phase I, II, and III 
clinical trials in multiple tumor types (bevacizumab Investigator Brochure, October 2005). 
The hemorrhagic events that have  been observed in bevacizumab clinical studies were 
predominantly tumor -associated hemorrhage (see below) and minor mucocutaneous 
hemorrhage.  
Tumor -Associated Hemorrhage:   Major or massive pulmonary hemorrhage or 
hemoptysis has been observed primarily in patients with NSCLC.  Life -threatening and 
fatal hemoptysis was identified as a bevacizumab -related adverse event in NSCLC 
trials.  These events occurred suddenly and presented as major or massive hemoptysis.  
Among the possible risk factors evaluated (inc luding squamous cell histology, treatment 
with anti -rheumatic/anti -inflammatory drugs, treatment with anticoagulants, prior 
radiotherapy, bevacizumab therapy, previous medical history of atherosclerosis, central 
tumor location, and cavitation of tumors dur ing therapy), the only variables that showed 
statistically significant correlations with bleeding were bevacizumab therapy and 
squamous cell histology.  
GI hemorrhages, including rectal bleeding and melena have been reported in patients 
with CRC, and have b een assessed as tumor -associated hemorrhages.  
Tumor -associated hemorrhages were also seen rarely in other tumor types and 
locations, including a case of CNS bleeding in a patient with hepatoma with occult CNS 
metastases and a patient who developed continuo us oozing of blood from a thigh 
sarcoma with necrosis.  
Mucocutaneous  Hemorrage:   Across all bevacizumab clinical trials, mucocutaneous 
hemorrhage has been seen in 20% -40% of patients treated with bevacizumab. These 
were most commonly NCI -CTC Grade [ADDRESS_54631] also been less common events of minor mucocutaneous hemorrhage in other 
locations, such as gingival ble eding and vaginal bleeding.  
Reversible Posterior Leukoencephalopathy Syndrome:   There have been rare 
reports of bevacizumab -treated patients developi[INVESTIGATOR_51675], a rare neurologic disorder that can present with the following 
signs and symptoms (among others):  seizures, headache, altered menta l status, visual 
disturbance, or cortical blindness, with or without associated hypertension.  Brain 
imaging is mandatory to confirm the diagnosis of RPLS.  In patients who deve lop RPLS, 
treatment of specific symptoms, including control of hypertension, is  recommended 
along with discontinuation of bevacizumab.  The safety of reinitiating bevacizumab 
therapy in patients previously experiencing RPLS is not known (Glusker et al. 200 6; 
Ozcan et al. 2006).   
   
 18 Congestive heart failure:   In clinical trials CHF was observed in all cancer indications 
studied to date, but predominantly in patients with metastatic breast cancer.  In the 
Phase III clinical trial of metastatic breast cancer (AV F2119g), 7 (3%) bevacizumab -
treated patients experienced CHF, compared with two  (1%) control arm patients.  
These  events varied in severity from asymptomatic declines in left ventricular ejection 
fraction (LVEF) to symptomatic CHF requiring hospi[INVESTIGATOR_51676].  All the 
patients treated with bevacizumab were previously trea ted with anthracyclines 
(doxorubicin cumulative dose of 240 −360 mg/m2).  Many of these patients also had prior 
radiotherapy to the left chest wall.  Most of these patients showe d improved symptoms 
and/or left ventricular function following appropriate medi cal therapy  (Miller et al. 2005).  
In a randomized, Phase III trial of patients with previously untreated metastatic breast 
cancer (E2100), the incidence of LVEF decrease (define d as NCI -CTC Grade 3 or 4) in 
the paclitaxel  + bevacizumab arm was 0.3% versus 0% for the paclitaxel alone arm.  
No information is available on patients with preexisting CHF of [LOCATION_001] Heart 
Association (NYHA) Class II −IV at the time of initiating bevacizu mab therapy, as these 
patients were excluded from clinical trials.  
Prior anthra cyclines exposure and/or prior radiotherapy to the chest wall may be 
possible risk factors for the development of CHF.  Caution should be exercised before 
initiating bevacizumab  therapy in patients with these risk factors.  
A Phase II trial in patients with  refractory acute myelogenous leukemia reported 5  cases 
of cardiac dysfunction (CHF or LVEF decrease to  40%) among 48  patients treated 
with sequential cytarabine, mitoxantrone , and bevacizumab.  All but 1 of these patients 
had significant prior exposure to anthracyclines as well (Karp et al. 2004).  
Other studies in patients with various tumor types and either a history of anthracycline 
exposure or concomitant use with bevacizu mab are ongoing.  
Patients receiving concomitant anthracyclines or with prior e xposure to anthracyclines 
should have a baseline MUGA scans or echocardiograms (ECHOs) with a normal 
LVEF.  
Neutropenia:   Increased rates of severe neutropenia, febrile neutropen ia, or infection 
with severe neutropenia (including some fatalities) have been observed in patients 
treated with some myelotoxic chemotherapy regimens plus bevacizumab in comparison 
to chemotherapy alone ( Sandler et al. 2006 ). 
Ovarian Failure : The incidenc e of new cases of ovarian failure (defined as 
amenorrhoea lasting 3 or more months,  FSH level ≥30 mIU/mL and a negative serum β-
HCG pregnancy test)  was prospectively evaluated in  a subset of 179 women receiving 
mFOLFOX chemothe rapy alone (n=84 or with bevac izumab  (n=95).  New cases of 
ovarian failure were identified in 34% (32/95) o f women receiving bevacizumab in  
combination with chemotherapy compared with 2% (2/84) of women receiving 
chemotherapy alone  [relative risk of 14 (95% CI 4, 53)]. After discontinua tion of 
bevacizumab treatment, recovery of ovarian  function at all time poin ts during the post -
treatment period was demonstrated in 22% (7/32) of the  bevacizumab -treated women. 
Recovery of ovarian function is defined as resumption of menses, a positive  serum β-
   
 [ADDRESS_54632], or a FSH level < 30 mIU/mL during the post -treatmen t period.  
Repeat dose safety stud ies in animals have shown that b evacizumab may have  an 
advers e effect on female fertility. Long term effects of the treatment with bevacizumab 
on fertility are unknown.  The risk of ovarian failure will be informed to female  with 
reproductive potential and fertility preservation strategies will be discussed prior to 
starting treatment with bevacizumab.  
Additional Adverse Events:   See the bevacizumab I nvestigator Brochure for additional 
details regarding the safety experience with bevacizumab.  
1.[ADDRESS_54633] the leukemia cell lines.12 
Phase I studies in patients with relapsed/refractory acute leukemias suggested 
temozolomide was well tolerated and had significant antileukemic activity when 
administered as a single agent. The maximum tolerated dose for this group of patients 
was determined to be 200 mg/m2/d for 7 days as induction and 200 mg/m2/d for [ADDRESS_54634] 
groups of patients: Patients with no detectable expression of O6-alkyl guani ne-DNA 
alkyltransferase  (MGMT) in leukemic blasts by [CONTACT_51713] a complete response 
rate of 40% and overall response rate of 60%. In contrast, patients who had detectable 
MGMT in leukemic cells (85 -90% of patients), had a 6% response rate to temozolo mide 
(p=0.003 comparing absent vs. present MGMT expression).[ADDRESS_54635] single -agent efficacy for advanced pancreatic 
NETs5,15 but even more encouraging results in combination with other agents  such as 
thalidomide1 and fluoropyrimidines .6,16,17  In particular, the Strosberg study showed 
particularly encouraging results6.  In this ret rospective study, 30 patients were  treated 
with capecitabine (750mg/m2 twice daily, days 1 -4) and temozolomide (200 mg/m2 
once daily, days 10 -14) every 28 days.  Among 30 patients treated, 21 (70%) had 
objective radiographic responses.   Median PFS was 18 months; OS at 2 years was 
92%.  A single arm Ph II prospective study of temozolomide and capecitabine  for NETs  
is ongoing ( R Fine (PI); [STUDY_ID_REMOVED]).  
 
1.3.1  Clinical Pharmacokinetics of Temozolomide  
Absorption: Temozolomide is rapi[INVESTIGATOR_51677] a peak plasma concentration (Cmax) achieved in a median Tmax of 1 hour. Food 
reduces the rate and extent of temozolomide absorption. Mean peak plasma 
concentration and AUC decreased by 32% and 9%, respectively, and median Tmax 
increased by 2 -fold (from 1 –2.25 hours) when temozolomide was administered after a 
modified high -fat breakfast.  
   
 20 A pharmacokinetic study comparing oral and intravenous temozolomide in 19 patients 
with primary CNS malignancies showed that 150 mg/m2 tem ozolomide for injection 
administer ed over 90 minutes is bioequivalent to 150 mg/m2 temozolomide oral capsules 
with respect to both Cmax and AUC of temozolomide and MTIC. Following a single 90 -
minute intravenous infusion of 150 mg/m2, the geometric mean Cma x values for 
temozolomide and MTIC  were 7.3 mcg/mL and 276 ng/mL, respectively. Following a 
single oral dose of 150 mg/m2, the geometric mean Cmax values for temozolomide and 
MTIC were 7.5 mcg/mL and 282 ng/mL, respectively. Following a single 90 -minute 
intravenous infusion of 150 mg/m2, t he geometric mean AUC values for temozolomide 
and MTIC were 24.6 mcg∙hr/mL and 891 ng∙hr/mL, respectively. Following a single oral 
dose of 150 mg/m2, the geometric mean AUC values for temozolomide and MTIC were 
23.4 mcg∙hr /mL and 864 ng∙hr/mL, respectively . 
The pharmacokinetics of temozolomide were evaluated in selected patients with 
advanced cancer in phase I clinical trials. Single -dose pharmacokinetics were determined 
in nine patients after intravenous (IV) dosing rangin g from 50 to 200 mg/m2, and in 25 
fasted patients following oral doses ranging from 200 to 1200 mg/m2. Pharmacokinetic 
parameters obtained in these patients are summarized in the following table:  
 
Parameter  Mean Value  Na CV (%)b 
Volume of distribution (L)  28.30  43 39 
Elimination half life (hr)  1.81 48 20 
Distribution half life (hr)  0.26 17 64 
Clearance (L hr-1) 11.76  42 35 
(a)N=number of observations (blood samples obtained).  
(b)CV=coefficient of variation.  
 
Oral bioavailability was studied by [CONTACT_51714] a one -hour infusion on two separate occasions at least 
four weeks apart. As shown in the following table, complete oral bioavailability was 
demonstrated in five of the subjects at 200 mg/m2. 
  
   
 21   
 
Patient Number  IV AUCa 
(mg·h·L-1) Oral AUC  
(mg·h·L-1)  
Fb 
5 32.16  41.00  1.27 
7 33.12  32.32  0.98 
15 35.96  41.67  1.16 
17 23.55  31.94  1.36 
19 25.30  16.93  0.67 
   Mean: 1.09  
(a)Area under the plasma concentration -time curve calculated by  [CONTACT_51715].  
(b)F= bioavailability calculated without consideration of the small differences in apparent 
elimination half life.  
 
As part of SPRI phase I study 193 -114-01, the pharmacokinetics of temozolomide were 
evaluated in 15 adult patients on  days 1 and 5 of treatment (3 patients each at oral doses 
of 100, 150, or 250 mg/m2/day, and 6 patients at 200 mg/m2/day). Temozolomide was 
rapi[INVESTIGATOR_24584] (mean T MAX range=0.33 -1.50 hr) and rapi[INVESTIGATOR_51678] (mean total body 
clearance, CL/F=~200 m./min)  following 5 consecutive days of administration. Elimination 
half-life was 1.8 hr. Pharmacokinetic parameters were similar on days 1 and 5, and 
temozolomide did not accumulate in plasma upon multiple dosing. Systemic exposure 
(AUC) increased linearly as do se increased from 100 to 250 mg/m2/day. Intra - and inter -
subject variability in plasma concentrations and pharmacokinetic parameters were small.  
Distribution: Temozolomide has a mean apparent volume of distribution of 0.4 L/kg 
(%CV=13%). It is weakly bound  to human plasma proteins; the mean percent bound of 
drug-related total radioactivity is 15%.  
Metabolism and Elimination: Temozolomide is spontaneously hydrolyzed at physiologic 
pH to the active species, MTIC and to temozolomide acid metabolite. MTIC is further 
hydrolyzed to 5 -amino -imidazole -4-carboxamide (AIC), which is known to be an 
intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is 
believed to be the active alkylating species. Cytochrome P450 enzymes play only a mi nor 
role in the metabolism of temozolomide and MTIC. Relative to the AUC of temozolomide, 
the exposure to MTIC and AIC is 2.4% and 23%, respectively.  
Excretion: About 38% of the administered temozolomide total radioactive dose is 
recovered over 7 days: 37. 7% in urine and 0.8% in feces. The majority of the recovery of 
radioactivity in urine is unchanged temozolomide (5.6%), AIC (12%), temozolomide acid 
metabolite (2.3%), and unidentified polar metabolite(s) (17%). Overall clearance of 
temozolomide is about 5 .5 L/hr/m2. Temozolomide is rapi[INVESTIGATOR_51678], with a mean 
elimination half -life of 1.8 hours, and exhibits linear kinetics over the therapeutic dosing 
range of 75 to 250 mg/m2/day.  
Effect of Age: A population pharmacokinetic analysis indicated that age ( range: 19 –78 
years) has no influence on the pharmacokinetics of temozolomide.  
   
 [ADDRESS_54636] of Gender : A population pharmacokinetic analysis indicated that women have an 
approximately 5% lower clearance (adjusted for body surface area) for temozolomide 
than men.   
Effect of Race : The effect of race on the pharmacokinetics of temozolomide has not been 
studied.  
Effect of Tobacco Use: A population pharmacokinetic analysis indicated that the oral 
clearance of temozolomide is similar in smokers and nonsmokers.  
Effect o f Renal Impairment: A population pharmacokinetic analysis indicated that 
creatinine clearance over the range of 36 to 130 mL/min/m2 has no effect on the 
clearance of temozolomide after oral administration. The pharmacokinetics of 
temozolomide have not been  studied in patients with severely impaired renal function 
(CLcr <36 mL/min/m2). Caution should be exercised when temozolomide is administered 
to patients with severe renal impairment.  
Effect of Hepatic Impairment: A study showed that the pharmacokinetics of temozolomide 
in patients with mild -to-moderate hepatic impairment (Child -Pugh Class I – II) were similar 
to those observed in patients with normal hepatic function.  
Effect of Other Drugs on Temozolomide Pharmacokinetics: In a multiple -dose study, 
admin istration of temozolomide c apsules with ranitidine did not change the Cmax or AUC 
values for temozolomide or MTIC.  
A population analysis indicated that administration of valproic acid decreases the 
clearance of temozolomide by [CONTACT_2902] 5%.  
A population analys is did not demonstrate any influence of coadministered 
dexamethasone, prochlorperazine, phenytoin, carbamazepi[INVESTIGATOR_050], ondansetron, H2 -
receptor antagonists, or phenobarbital on the clearance of orally administered 
temozolomide.  
1.3.2  Adverse Reactions:  
The mo st common reactions to Temozolomide include nausea, vomiting, 
headache, fatigue and hematologic effects.  These events are usually mild to 
moderate.  Nausea and vomiting is usually readily controlled with antiemetics.  
Myelosuppression (thrombocytopenia an d neutropenia) is the dose -limiting side 
effect.  It usually occurs within the first few cycles of therapy and is not cumulative.  
In prior studies, myelosuppression occurred late in the treatment cycle and 
returned to normal, on average, within [ADDRESS_54637] been reported  infrequently  in patients 
receiving temozolomide.  Liver toxicity may occur several weeks or more after 
initiation of treatment or after temozolomide discontinuation.  For patients with 
significant liver function abnormalities the benefits and risks of continuing 
treatment will be carefully considered.  
   
 23 Other less common side effects may include somnolence or insomnia, anorexia, 
constipation, diarrhea, we ight loss, abdomin al pain, rash, pruritis, anxiety, depression, 
pain when swallowing, hyperglycemia,  ] =-kidney abnormalities , Stevens -Johnson -
Syndrome, PCP  infection , secondary malignancy, and aplastic anemia.  
1.3.[ADDRESS_54638] shown that MGMT 
epi[INVESTIGATOR_51679], as determined by [CONTACT_51716] -specific 
polymerase -chain -reaction analysis, was an independent favorable prognostic factor in 
patients with glioblastoma multiforme treated with temozo lomide.18,21  
Interestingly, there is compelling evidence that protracted schedules  of temozolomide 
may lead to  an 'autoenhancement' of its inherent cytotoxic potential by [CONTACT_51717]'s capacity for MGMT -mediated DNA repair and resistance. O6-alkyl 
guanine -DNA alkyltransferase activity was measured in the PBMCs of pa tients treated on 
two phase I protracted temozolomide studies. Patients were treated daily with various 
temozolomide doses (75 -175 mg m-2) and treatment duration (7 -21 days), and levels of 
MGMT inactivation and regeneration, as well as the relation between  MGMT inactivation 
and toxic ity, were studied. This study determined that protracted, relatively low -doses 
(100mg/m2) of temozolomide given daily for 14 days leads to marked inactivation of 
MGMT (~80%).[ADDRESS_54639] and colorectal cancers.   
 
1.4.1 Capecitabine Safety Profile  
 
Capecitabine Monotherapy –in Colorectal and Breast carcinoma: The safety 
database for monotherap y consists of [ADDRESS_54640] frequently reported adverse events (AEs) among patients 
receiving capecitabine monoth erapy as treatment for breast and CRC were hand -foot 
syndrome (HFS), diarrhea, nausea, vomiting, stomatitis and fatigue. The majority of 
treatment -related AEs w ere mild to moderate in intensity. The treatment -related grade 
3and [ADDRESS_54641] incid ences were HFS (grade 3 only), diarrhea, and nausea. 
   
 [ADDRESS_54642] of the grade 4 treatment -related AEs was in the gastrointestinal (GI) system. The 
incidence of treatme nt-related serious AEs (SAEs) was low. The most frequent 
treatment -related SAEs (i.e., those rep orted in ≥2% of patients) were diarrhea, 
dehydration, vomiting, nausea, and stomatitis. HFS was reported as a SAE in only two 
patients (<1%). The overall safety  profile of capecitabine monotherapy as adjuvant 
treatment for stage III colon cancer was similar to that  observed in the pooled 
monotherapy metastatic CRC and breast cancer safety database.  
 
Capecitabine in combination with oxaliplatin and bevacizumab (XE LOX+BV) in 
colorectal cancer : the most frequently occurring AEs in patients with mCRC who 
received first -line treatment with X ELOX+BV were nausea, vomiting and parasthesia.  
There was a moderate increase in the incidence of vomiting and PPE. Diarrhea was the 
most common grade 3/4 AE (unrelated and related to treatment) as well  as the most 
common treatment -related SAE. An increa se in the incidence of vascular disorders was 
observed, mainly due to the incidence of deep vein thrombosis.  
 
Additional Adverse Events:   See the capecitabine  Investigator Brochure for additional 
details regarding the safety experience wi th capecitabine . 
1.[ADDRESS_54643] be synergistic.2  Additionally, temozolomide 
can safely be combined with bevacizumab8.  For patients who need an objective 
response  (due to rapid disease progression, bulky tumors, or symptomatic disease) we 
are in need of a well -tolerated regimen that yields high response rates.  To date, the 
temozolomide/capecitabine restrospective data is the most promising chemotherapy 
backbo ne.  There is sound scientific rationale that bevacizumab is also active in this 
disease and will hopefully be additive or synergistic with temozolomide/capecitabine.   
Capecitabine and Bevacizumab are routinely used safely in the setting of metastatic 
colorecta l cancer.   We do not an ticipate safety issues for the 
Temozolomide/Capecitabine/Bevacizumab drug combination.   We, therefore, propose a 
multi -institution, phase II, single -arm, non -randomized study investigating bevacizumab 
in combination with temozol omide  and capecitabine for patients with unresectable or 
metastatic  pancreatic neuroendocrine tumors.  
1.[ADDRESS_54644] Perfusion:   
   
 25 Perfusion computed tomography (CT) imaging has been established for many years in  
stroke imaging. With the introduction of multi -detector row CT technology increasing 
substantially the spatial and temporal resolution as well as offering new detector array 
configurations, CT perfusion imaging has become feasible for assessment of tumor 
perfusion in applications outside the brain, including the abdomen. Recent studies 
indicate that perfusion CT can be performed successfully in patients with NETs .24,[ADDRESS_54645] been assessed in patients with NETs and 
compared to normal tissue including blood flow (BF), blood volume (BV), mean transit 
time (MTT), time to peak (TTP ), permeability surface, and volume transfer constant 
(Ktrans). The implications of those parameters on grade of tumor vascularization, 
correlation with ex vivo parameters of angiogenesis including microvessel density (MVD), 
or expression profiles of molec ular markers of tumor angiogenesis such as vascular 
endothelial g rowth factor receptor (VEGFR) or integrins in NETs still need to be assessed. 
However, a recent study in patients with pancreatic endocrine tumors undergoing 
preoperative perfusion CT has sho wn high correlation between the tumor BV parameter 
as assessed by  [CONTACT_51718], as well as histoprognostic factors 
such as proliferation index and WHO classification obtained from tumor samples.[ADDRESS_54646] doses of 
bevacizumab.  
MGMT testing:  
Evaluation of MGMT status by [CONTACT_51719] (IHC)  
Temozolomide is an alkyla ting agent initially developed as an oral and more easily 
tolerated alternative to dacarbazine. The c ytotoxic effect of temozolomide has been 
   
 26 attributed to its ability to induce DNA methylation at the O6 position of guanine. 
Methylation of guanine results in DNA mismatch, ultimately resulting in apoptosis and 
tumor cell death.17 The sensitivity of tumor c ells to alkylating agents, including 
temozolomide, has been associated with decreased levels of the DNA repair enzyme, 
O6-methylguanine DNA methyltransfera se (MGMT), which, through its ability to restore 
DNA to its normal form, can prevent chemotherapy -induced cell death.[ADDRESS_54647] been associated with clinical benefit and enhanced survival in 
melanoma and glioblastoma patients treated with temozolomide.19-23 
In a study by [CONTACT_51711], et al., 97 archival neuroendocrine tumors specimens were  
evaluated for MGMT deficiency by [CONTACT_9064].8 Among 37 pancreatic 
neuroendocrine tumors evaluated, 19 (51%) were MGMT deficient. Non -functional 
tumors included similar proportions of MGMT intact and MGMT deficient tumors. Three 
of 10 insulinomas  were MGMT deficient; both gastrinomas and the single evaluated 
glucagonoma were also MGMT deficient. In contrast, MGMT was present in all 60 
carcinoid tum ors (20 typi[INVESTIGATOR_51680], 20 atypi[INVESTIGATOR_51681] 
20 small intestine carcino ids) evaluated.    Among 21 patients with evaluable tumor 
tissue who had also received treatment with temozolomide, 4 of 5 patients with MGMT -
deficient tumo rs (all pancreatic NETs) and [ADDRESS_54648] tumors 
responded to treatment (p=0.001 ). 
 
Evaluation of MGMT status by [CONTACT_51720]. Gliomas are the most common primary brain 
tumors. Grade IV gliomas, also known as glio blastoma multiforme (GBM) are highly 
malignant tumors that account for almost a third of primary brain tumors in adults. 
Patients with gliomas that exhibit ed promoter methylation of the MGMT gene showed 
modestly longer survival after treatment with alkylat ing chemotherapeutics than patients 
whose gliomas did not show MGMT promoter methylation.   Clinical trials to evaluate the 
use of MGMT promoter methylation  to predict response to alkylating agents have also 
been designed for patients with acute myeloid leu kemia, neuroendocrine tumors, and 
other cancers.  
 
The mechanisms of MGMT regulation in neuroendocrine tumors remain unknown. 
Silencing of the MGMT gene by [CONTACT_51721] a common 
mechanism of MGMT regulation in other tumor types. In pat ients with glioblastoma, 
MGMT promoter methylation is associated with improved survival and benefit from 
temozolomide.22,[ADDRESS_54649] found either no significant difference in MGMT prom oter methylation 
rates between carcinoid and pancreatic neuroendocrine tumors, or higher rates of 
promoter methylation in carcinoid tumors compared to panc reatic neuroendocrine 
tumors.25,26 
 
Further studies to evaluate whether promoter methylation is a com mon MGMT silencing 
mechanism in neuroendocrine tumors, and whether promoter methylation correlates 
with immunohistochemical absence of MGMT, are warranted.  
 
   
 27 2.0 Objectives  
a. Primary Objective  
i. To investigate if the combination of capecitabine and temozolomide  with 
bevacizumab for metastatic or unresectable neuroendocrine tumors will 
improve RR by 62% over historical controls (null RR of 40% to true RR  
65%). 
ii. Assess the toxicities using CTCAE v4.0.  
 
b. Secondary Objectives  
i. To evaluate progression -free survival (PFS ) and overall survival (OS) 
using Kaplan -Meier analysis  
ii. To assess MGMT by [CONTACT_51722]. To assess serum hormone marker levels  
iv. To evaluate CT Perfusion as a tool to predict early therapeutic response  
(OPTIONAL)  
v. To bank serum for future correlative ana lyses  
3.[ADDRESS_54650] scans at baseline and a fter every 
3 cycles (approximately 3 months) and be evaluated by [CONTACT_13407].  We estimate 
that most patients will co mplete 6 -9 cycles of treatment.  Dose reductions are allowed 
after cycle 1. If, after 3 cycles, patients develop significant toxicities  attributed to either 
temozolomide (including nausea, cytopenias, etc) or capecitabine (including diarrhea, 
hand -foot ski n syndrome, etc) patients may discontinue these agents and continue 
receiving bevacizumab as a single agent.  We will continue treatmen t indefinitely until one 
of the following occurs: patient withdraws consent and decides to discontinue study 
treatment, d evelopment of unacceptable toxicities, or evidence for progression of 
disease. If a patient is on single -agent bevacizumab at the time of disease progression, 
temozolomide and capecitabine may be restarted at the discretion of the investigator.  
 
 Bevacizumab 10  mg/kg IV day 1 and 15  
Capecitabine 750 mg/m2 po BID days 1 -14 
Temozolomide 200  mg/m2 po QD  days 10 -14 
Repeat Q28 days x 3 cycles  R
E
G
I
S
T
E
R Screening 
evaluation  Continue until 
disease 
progression  
   
 28 This w ill be a Phase II study evaluating capecitabine, temozolomide, and bevacizumab 
in patients with unresectable or metastatic pancreatic neuroendocrine tumors.   
 
A sample size of 30 patients would give 80% power to reject the null RR of 40% if the 
true RR is  65% or higher.  The null hypothesis is based on a prospective phase II study 
conducted by [CONTACT_51711], et al evaluating the efficacy of temozolomide and thalidomide.1  In 
this study, 29 patients with mixed metastatic NETs were treated with temozolomide 150 
mg/m2 for 7 days every other week and thalidomide at doses of 50 -400 mg daily.  The 
overall radiographic response was 25% (45% in patients with pancreatic NETs).  Th e 
alternative hypothesis is based on the more recent retrospective study reported by 
[CONTACT_51712], et al in which patients were treated with capecitabine (750mg/m2 twice daily, 
days 1 -14) and temozolomide (200 mg/m2 once daily, days 10 -14) every 28 days6.  Of 
30 patients treated, the RR was 70%.  
3.[ADDRESS_54651] chosen a multisite study for this rare 
disea se to enhance accrual rates.  Our planned doses of bevacizumab, capecitabine, and 
temozolomide  are routinely  used in GI and other malignancies.  
3.3 Outcome Measures  
3.3.1  Primary  
a. RR %  (by [CONTACT_393] v1.1 ) 
b. Toxicities according to CTCAE v4.0.  
3.3.2  Secondary  
c. PFS ( median in months)  and OS (median in months)  
d. MGMT by [CONTACT_51723]  
e. Serum hormone marker analysis  
f. CT perfusion  
i. Correlation of the CT perfusion parameters with:  
1. Progression free survival  
2. Overall survival  
3. RECIST criteria  
ii. Correlation of early perfusi on parameters (from baseline, 2 -week, and 
9-week follow -up scans)  
g. Serum to be stored for future correlative studies  
 
3.3.[ADDRESS_54652] laboratory tests (including CBC with differential and comprehen sive 
metabolic panel) performed every [ADDRESS_54653] of medical interviews, recording of adverse events, physical 
examinations, blood pressure, and laboratory measurements.  Patients will be evaluated  
for adverse events (all grades), serious adverse events, and adverse events requiring 
study drug interruptio n or discontinuation at each study visit for the duration of their 
participation in the study.  Patients discontinued from the treatment phase of t he study for 
any reason will be evaluated ~30  days (28 –42 days) after the decision to discontinue 
treatmen t.  
Specific monitoring procedures are as follows:  
• Hypertension will be monitored through routine evaluation of blood pressure prior to 
each bevacizum ab treatment.  Optimal control of blood pressure according to standard 
public health guidelines is recommende d for patients on treatment with or without 
bevacizumab.  
• Proteinuria will be monitored by [CONTACT_51724], urinalysis, or 24hour urine  and graded 
as shown in the following table.31,32 Proteinuria will be managed  per guidelines outlined 
in section 6.1.3  
Protein dipstick grading  
 
Designation  Approx. amount  
 
Concentration  Daily  
Trace  5–20 mg/dL  
  
 
1+ 30 mg/dL  
 Less than 0.5 g/day  
 
2+ 100 mg/dL  
 0.5–1 g/day  
 
3+ 300 mg/dL  
 1–2 g/day  
 
4+ More than 300  mg/dL  
 More than 2 g/day  
 
 
• If patients on treatment wi th bevacizumab require elective major surgery, it is 
recommended that bevacizumab be held for 4 -8 weeks prior to the surgical procedure. 
   
 30 Patients undergoing a major surgical procedure should not begin/restart bevacizumab 
until 4 weeks after that procedure (in the case of high risk procedures such as liver 
resection, thoracotomy, or neurosurgery, it is recommended that chemotherap y be 
restarted no earlier than 6 wk and bevacizumab no earlier than 8 wk after surgery).   
Temozolomide and/or capecitabine may als o be held at the discretion of the 
investigator.  
4.2 Other Study Drug(s) -Specific  
Please see Section 6.[ADDRESS_54654] ions for the management of study drug –
related toxicities.  
5.[ADDRESS_54655] histologica lly confirmed pancreatic neuroendocrine tumors 
that are considered low or intermediated grade as defined by [CONTACT_51725], et al  (to 
include Ki -67 and mitotic index) .[ADDRESS_54656] metastatic or unresectable disease  
3. Patients with prior surgical resection who develop radiological or clin ical 
evidence of metastatic cancer do not require separate histological or cytological 
confirmation of metastatic disease u nless an interval of > [ADDRESS_54657] dose on this study.  
5. Concurrent somatostatin analogues are allowed provided that patients 1) have 
been on stable doses x 8 weeks and 2) have documented disease progression 
on that dose.  
6. Prior liver directed therapi[INVESTIGATOR_51682] (ie. chemoembolization, 
radioembolization) as long as target lesions in the liver have demonstrated 
growth since the li ver directed treatment.  
7. Prior peptide receptor radionuclide therapy (PRRT) will be permitted as long as 
target lesions in the liver have demonstrated growth since the liver directed 
treatment.  
8. Low-dose aspi[INVESTIGATOR_248] (≤ 325 mg/d) may be continued in subjects at h igher risk for 
arterial thromboembolic disease.  
9. Patients must have a primary or metastatic lesion measurable in at least one 
dimension by  [CONTACT_51726]  v1.1 (see Section 4.2) within [ADDRESS_54658] be ≥ 18 years of age . 
12. Laboratory values ≤ 2 weeks prior to start date (may be supported by 
[CONTACT_51727]/or hematopoetic growth factors) : 
• Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L (≥ 1500/mm3)  
• Platelets (PLT) ≥ 100 x 109/L (≥ 100,000/mm3) 
• Hemoglobin (Hgb) ≥ 9 g/dL  
• Serum creatinine ≤ 1.[ADDRESS_54659]  
• Serum bilir ubin ≤ 1.[ADDRESS_54660]   
• Aspartate aminotransferase  (AST/SGOT), alanine aminotransferase 
(ALT/SGPT) ≤ 3.[ADDRESS_54661] (≤ 5.[ADDRESS_54662] if liver metastases present).  
Note:  ERC P or percutaneous stenting may be used to normalize the 
liver function tests.  
13. Life expectancy ≥ 12 weeks . 
14. Ability to give written informed co nsent according to local guidelines . 
5.2 Exclusion Criteria     
Disease -Specific Exclusions  
1. Prior bevacizumab  and any cytotoxic chemotherapy.  
2. Poorly differentiated or high grade pancreatic neuroendocrine  tumors  
3. Prior full field radiotherapy ≤ 4 weeks or li mited field radiotherapy ≤ [ADDRESS_54663] 6 months following 
the comple tion of curative intent therapy , specifics as follows:  
• Curatively resected non -melanomatous skin cancer  
• Curativel y treated cervical carcinoma in situ  
• Patients with organ -confined prostate cancer with no evidence of 
recurrent or progressive disease based on prostate -specific antigen 
(PSA) values are also eligible for this study if hormonal therapy has 
been initiated o r a radical prostatectomy has been performed.  
   
 32 • Other primary solid tumor curatively treated with no known active 
disease present and no treatment administered for the last [ADDRESS_54664] 
receive d investigational drugs ≤ 4 weeks prior to enrollment.  
6. Known h ypersensit ivity to capecitabine, temozolomide , or any component 
of the formulation and or a known deficiency of dihyropyrimidine 
dehydrogenase.  
General Medical Exclusions  
Subjects meeting any of  the following criteria are ineligible  for study entry:   
7. Inability to c omply with study and/or follow -up procedures . 
8. Current, recent (within [ADDRESS_54665] infusion of this study), or planned 
participation in an experimental drug study . 
9. Pregnancy (p ositive pregnancy test) or lactation - breast feeding Lack of  of 
effectiv e means of contraception (men and women) in subjects of child -
bearing potential.  
10. Uncontrolled systemic fungal, bacterial, viral, or other infection (defined as 
exhibiting ongoing signs /symptoms related to the infection and without 
improvement, despi[INVESTIGATOR_51683]).  
11. Known history of HIV, HBV, or HCV  
12. Current, ongoing treatment with full -dose warfarin .  However patients may 
be on stable doses of a low molecu lar weight heparin are allowed  (ie. 
Lovenox).   
Bevacizumab -Specific Exclusions  
13. Inadequately controlled hypertension (defined as systolic blood pressure 
150 mmHg and/or diastolic blood pressure > 100 mmHg) . 
14. Prior history of hypertensive crisis or hyperten sive encephalopathy . 
15. [LOCATION_001] Heart Association (NYHA) Grade II or greater congestive heart 
failure (see Appendix E) . 
16. History of myocardial infarction or unstable angina  within 6 months prior to 
Day 1 . 
17. History of stroke or transient ischemic attack  within 6 months prior to Day 
1. 
18. Known CNS metastases  
19. Significant vascular disease (e.g., aortic aneurysm, requiring surgical 
repair or recent peripheral arterial thrombosis) within 6 months prior to 
Day 1 . 
   
 33 20. History of GI bleeding ( hemoptysis /melena/hematochezia,   1/2 teaspoon 
of bright red blood per epi[INVESTIGATOR_1865]) within 1  month prior to Day 1 . 
21. Evidence of bleeding diathesis or significant coagulopathy (in the absence 
of therapeutic anticoagulation) . 
22. Major surgical procedure, open biopsy, or sign ificant traumatic injur y 
within 28  days prior to Day 1 or anticipation of need for major surgical 
procedure during the course of the study . 
23. Core biopsy or other minor surgical procedure, excluding placement of a 
vascular access device, within 7 days prior to Day 1 . 
24. History of ab dominal fistula or gastrointestinal perforation within 6 months 
prior to Day 1 . 
25. Serious, non -healing wound, active ul cer, or untreated bone fracture . 
26. Proteinuria: Patients are allowed to have 0, trace, or 1+ protein by [CONTACT_51728] l, if >= 2+ must check 24h urine protein and 
must be < 1g to start study.   
27. Known hypersensitivity to any component of bevacizumab .  
 
6.0 Study Medications   
 
6.1  Bevacizumab administration, storage, and toxicity management  
Bevacizumab is a clear to slight ly opalescent, colorless to pale brown, sterile liquid 
concentrate for solution for intravenous (IV) infusion.   Bevacizumab may be supplied in 
5-cc (100 -mg) and 20 -cc (400 -mg) glass vials containing 4 mL or 16 mL bevacizumab , 
respectively (all at 25 mg/mL) .  Vials contain bevacizumab with phosphate, trehalose, 
polysorbate 20, and Sterile Water for Injection (SWFI), USP.   Vials contain no 
preservative and are suitable for single use only.  
Bevacizumab will be supplied by [CONTACT_51729]/[COMPANY_002] as the commercially av ailable form 
of this medication.  
For further details and molecule characterization, see the bevacizumab Investigator 
Brochure.  
6.1.1 Bevacizumab Administration  
Bevacizumab will be initiated at a dose of 10 mg/kg IV on days 1 and 15 of a 28 -day 
cycle. Dose will be based on actual weight and subsequent doses will remain the same 
unless there is a +/ - 5% change from the actual weight.  
It will be diluted in a total volume of 100mL of 0.9% Sodium Chloride Injection, USP.  
Administration will be as a continuous IV infusion.  Anaphylaxis precautions should be 
   
 [ADDRESS_54666] dosing based 
on ideal weight.  
The initial dose will be d elivered over 90 [ADDRESS_54667] infusion is tolerated 
without infu sion-associated adverse events (fever and/or chills) the second infusion may 
be delivered over 60 10 minutes.  If the 60 -minute infusion is well tolerated, all 
subsequent infusion s may be delivered over 30 [ADDRESS_54668] experiences an infusion –associated adverse event, he or she may be 
premedicated for the next study drug infusion; however, the infusion time may not be 
decreased for the subsequent infusion.  If the nex t infusion is well tolerated with 
premedication, the subsequent infusion time  may then be decreased by 30 [ADDRESS_54669] experiences an 
infusion -associated adverse event with the 60 -minute infu sion, all subsequent doses 
should be given over 90 [ADDRESS_54670] experiences an 
infusion -associated adverse event with the 30 -minute infusion, all subsequent doses 
should be given over 60 10 minutes.  
6.1.2 Bevacizumab Storage  
Upon re ceipt of the study drug, vials are to be refrigerated at 2 C–8C  
(36F–46F) and should remain refrigerated until just prior to use.  DO NOT FREEZE.  
DO NOT SHAKE.  Vials should be protected from light.  
Opened vials must be used within [ADDRESS_54671]. Bevacizumab has a terminal half -life of 21 days; 
therefore, its discontinuation results in slow elimination over several months. There is no 
available antidote for bevacizumab.  
Subjects should be assessed clinically fo r toxicity prior to, during, and after each infusion. 
If unmanageable toxicity occurs because of bevacizumab at any time during the study, 
treatment with bevacizumab should be dis continued.  
Infusion Reaction:  Infusion of bevacizumab should be interrupted for subjects who 
develop dyspnea or clinically significant hypotension. Subjects who experience a NCI 
CTCAE v 4.0 Grade 3 or 4 allergic reaction / hypersensitivity, adult respi[INVESTIGATOR_51684], or bronchospasm (regardless of grade) will be discontin ued from bevacizumab 
treatment.  
The infusion should be slowed to 50% or less or interrupted for subjects who experience 
any infusion -associated symptoms not specified above. When the subject’s symptoms 
   
 [ADDRESS_54672] completely resolved, the infusion may be continue d at no more than 50% of the rate 
prior to the reaction and increased in 50% increments every 30 minutes if well tolerated.  
Infusions may be restarted at the full rate during the  next cycle.  
Adverse events requiring delays or permanent discontinuation of  bevacizumab are listed 
in Table 1  
Regardless of the reason for holding bevacizumab , the maximum allowable length of 
treatment interruption is 2 months.  
   
 36 Table1:  
Bevacizumab Dose Management Due to Adverse Events  
 
Event  Action to be Taken  
Hypertension  
No dose modifications for grade 1/2 events  
Grade 3  If not controlled to 150/100 mmHg with medication, discontinue 
bevacizumab.  
Grade 4 (including 
hypertensive 
encephalopathy)  Discontinue bevacizumab.  
Hemorrhage  
No dose modifications for grade 1/[ADDRESS_54673] bevacizumab held until all of the 
following criteria  are met:  
• The bleeding has resolved and hemoglobin is stable.  
• There is no bleeding diathesis that would increase the 
risk of therapy.  
• There is no anatomic or pathologic condition that 
significantly increases the risk of hemorrhage 
recurrenc e. 
Subjects who experience a repeat Grade [ADDRESS_54674] bevacizumab held until all of the 
following criteria  are met:  
• The bleeding has resolved and hemoglobin is stable.  
• There is no bleeding diath esis that would increase the 
risk of therapy.  
• There is no anatomic or pathologic condition that 
significantly increases the risk of hemorrhage 
recurrence.  
 
   
 37 Grade 2, 3, or 4 
pulmonary or CNS 
hemorrhage  Discontinue bevacizumab  
Venous Thrombosis  
No dose mod ifications for grade 1/2 events  
Grade 3 or 4  Hold bevacizumab.  If the planned duration of full -dose 
anticoagulation is <2  weeks, bevacizumab  should be held until 
the full -dose anticoagulation period is over.  If the planned 
duration of full -dose anticoa gulation is >2 weeks, bevacizumab 
may be resumed during the period of full -dose anticoagulation if 
all of the following criteria  are met:  
• The subject must have an in -range INR (usually 
between 2 and 3) if  on warfarin; LMWH, warfarin, or 
other anticoagulan t dosing must be stable prior to 
restarting bevacizumab treatment.  
• The subject must not have had a Grade 3 or 4 
hemorrhagic event while on anticoagulation.  
Arterial Thromboembolic event  
(New onset, worsening, or unstable angina, myocardial infarction, tra nsient ischemic 
attack, cerebrovascular accident, and any other arterial thromboembolic event)  
 Any grade  Discontinue bevacizumab.  
Congestive Heart Failure (Left ventricular systolic dysfunction)  
No dose modifications for grade 1/2 events  
Grade 3  Hold bevacizumab until resolution to Grade ≤ 1.  
Grade 4  Discontinue bevacizumab.  
Proteinuria  (note: urine protein -to-creatinine ratio not allowed ) 
 Grade 1  No bevacizumab dose  modifications . 
 Grade 2  
 
 Suspend  bevacizumab for ≥ 2 grams / 24 hours, and resume  
when proteinuria is < 2 grams / 24 hours.  
For 2+ urinalysis/ dipstick: Ok to treat, but o btain 24 hour urine 
prior to next bevacizumab dose.  
For 3+ urinalysis/ dipstick: Ok to treat, but o btain 24 hour urine 
prior to bevacizumab dose.  
 Grade 3  Suspend  bevacizumab. Resume when proteinuria is < 2 grams / 
24 hours  as determined by 24 hour urine collection  
Grade 4 
(nephrotic 
syndrome)  Discontinue bevacizumab.  
GI Perforation  Discontinue bevacizumab.  
   
 38 Fistula    
Any grade (TE 
fistula)  Discontinue bevacizumab.  
Grade 4 fistula  Discontinue bevacizumab.  
Bowel Obstruction  
Grade 1   
Continue patient on study for partial obstruction NOT requiring 
medical intervention.  
Grade 2  Hold bevacizumab for partial obstruction requiring medical 
intervention.  Patient may resta rt upon complete resolution.  
Grade 3/4  Hold bevacizumab for complete obstruction.  If surgery is 
necessary, patient may restart bevacizumab after full recovery 
from surgery, and at investigator’s discretion.  
Wound dehiscence 
Any grade  (requiring 
medical or surgical 
therapy)   
Discontinue bevacizumab.  
Reversible Posterior Leukoencephalopathy  
Any grade 
(confirmed by [CONTACT_9268])  Discontinue bevacizumab.  
Other Unspecified Bevacizumab -Related Adverse Events  
Grade 3  
Grade 4  Hold bevacizumab until recovery to ≤ Grad e 1 
Discontinue bevacizumab.  
  
Hematological Toxicities  (for Day 15, Bevacizumab infusion only)  
ANC  
Grade 1/2/3  No dose modifications  
Grade 4  Hold dose  
Platelets  
Grade 1 /2 No dose modifications  
Grade 3/4  Hold dos e 
 
 
  
   
 39 6.2 Temozolomide  administration, storage, and toxicity management  
Temozolomide [8-carbamoyl -3-methylimidazo(5,1 -d)-1,2,3,5 -tetrazin -4(3H) -one] 
(Temodal) is an imidazole tetrazinone compound developed by [CONTACT_51730] -Plough for use 
as an antineoplastic a gent.  TMZ is a prodrug that spontaneously hydrolyzes to 5 -(3-
methyltriazen -1-yl)imida zole-4-carboxamide (MTIC), which is also the active metabolite 
of dacarbazine. Dacarbazine, however, requires hepatic metabolism for formation of this 
metabolite, which r esults in variable levels.  TMZ is stable at an acidic pH, allowing oral 
absorption, a nd has a broad biodistribution.  
Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at 
physiologic pH to the reactive compound 5 -(3-methyltria zen-1-yl)-imidazole -4-
carboxamide (MTIC). The cytotoxicity of MTIC is thought to be pr imarily due to alkylation 
of DNA. Alkylation (methylation) occurs mainly at the O 6 and N 7 positions of guanine.  
The inactive ingredients for temozolomide Capsules are as follows: lactose anhydrous 
(132.8 mg), colloidal silicon dioxide (0.2 mg), sodium star ch glycolate (7.5 mg), tartaric 
acid (1. 5 mg), and stearic acid (3 mg).  
 
The body of the capsules are made of gelatin, and are opaque white. The cap is also 
made of gelat in, and the colors vary based on the dosage strength. The capsule body 
and cap are imp rinted with pharmaceutical branding ink, which contains shellac, 
dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, purified water, 
strong ammonia so lution, potassium hydroxide, and ferric oxide.  
 
Temozolomide capsules are supplied in amber glass bottles containing 5, 14, or [ADDRESS_54675] gelatin 
capsules in the following p.o. dose s trengths: 5mg. 20mg. 100mg. 140mg. 180mg, and 
250mg. Each capsule contains the active drug substance in combination with lactose, 
anhydrous NF, colloidal silicon dioxide NF, sodium starch glycolate NF, tartaric acid NF, 
and stearic acid NF.  The capsule sh ells contain gelatin NF, titanium dioxide USP, and 
sodium lautyl sulfate NF.  T emozolomide is commercially available. Temozolomide is 
supplied in preservative free, [ADDRESS_54676] gelatin capsules.   
 
Agent Ordering  
Temozolomide is being provided by [CONTACT_44873].  Commercial Temozolomide will be used in 
this study. Temozolomide will be shippe d directly to all sub -sites from [COMPANY_006].  
 
6.2.1 Temozolomide Administration:  
Oral temozolomide will be given at a dose of 200 mg/m2 PO once dai ly for days 10 -14 at 
bedtime.  Bod y Surface Area ( BSA) will be calculated based on adjusted ideal body 
weight. The temozolomide dose will be capped at [ADDRESS_54677] be administered wh ole. Temozolomide missed doses will not be made up, and 
patients should not double -up on missed doses during treatment.  
   
 40  
6.2.2 Temozolomide Storage:  
As a solid, temozolomide is thermally stable and does not decompose when exposed to 
light. In solution, te mozolomide undergoes rapid hydrolysis in a basic environment. The 
product label rec ommen ds storage at room temperature 25°C (77°F).   Temozolomide 
should be stored at 20 -25°C (68 -77°F), excursions permitted between 15 -30°C (59 -86°F). 
Care will be taken to m aintain an acceptable storage temperature. The clinical supplies 
storage area at th e site will be monitored by [CONTACT_51731]. Documentation of temperature monitoring will be maintained on 
site. 
 
Agent Accountability  
Investigational clinical supplies must be received by a designated person at the study 
site, handled and stored safely and properly, and kept in a secured location to which only 
the investigator and designated assistants have ac cess. Clinical supplies are to be 
dispensed only in accordance with the protocol. The investigator is responsible for 
keepi[INVESTIGATOR_51685], the 
amount dispensed to and returned by [CONTACT_748]/pat ients, and the amount remain ing at 
the conclusion of the study. Stanford pharmacy must be kept informed of subsite drug 
shipments, use, and destruction.  
 
In accordance with Good Pharmacy Practices, gloves should always be worn by [CONTACT_51732] (i.e., when counting 
returns). The Principal Investigator, Stanford  study coordinator, or the investigative 
pharmacy at Stanford  should be contact[CONTACT_51733].  
 
Due to biohazard concerns, unused study drug will be destroyed locally and not sent back 
to [COMPANY_006] & Co, Inc. Drug will be destroyed according to standard operating procedures 
of the institutional pharmacy.  
 
Drug accountability: temoz olomide may not be used outside the scope of this protocol, 
nor can temozolomide be transferred or licensed to any party not participating in this 
clinical study. Opened bottles returned by [CONTACT_51734] p atient -
specific investigatio nal Agent Accountability Record (i.e. logged in as “returned by 
[CONTACT_1962]” and logged out as “for destruction”) and destroyed on -site in accordance with 
institutional policy.  
 
6.2.3  Temozolomide Dose Modifications:   
The dose of  temozolomide will be determined according to (1) non -hematologic AEs 
during the previous cycle, as well as (2) the lowest ANC and platelet counts during that 
cycle.  
 
   
 41 • Dose reductions: For non -hematologic grade 3 AEs (except for nausea and 
vomit ing as well  as AEs unrelated to treatment) the dose should be reduced 
according to the Temozolomide Dose Level Table. Dose reductions for treatment 
day ANC and platelet counts should also be made according to the Dose Level 
Table below. Each dose reduction  will be a 20% reduction from the prior level. 
No dose escalation of temozolomide is permitted  
 
• Discontinuation: For patients who require more than [ADDRESS_54678] possibly related to study treatme nt recur af ter reduction for that AE, th en 
temozolomide will be stopped.  
 
Temozolomide Dose Level Table  
Dose Level  Dose in 
mg/m2 
0 200 
-1 160 
-2 128 
* Note this is a 20% dose reduction with each dose level  
 
Hematologic Toxicity  
ANC (/ mm³)  Platelets (/ mm³) % of Planned 
Temozolomide  
> 1500/mm³  And > 100,000/mm3 100%  
750-1499 /mm³  Or 50,000 -
99,999/ mm3 Hold then dose 
reduce * 
< 750/mm³  or < 50,000/ mm3 Hold then dose 
reduce ** 
 
*Upon recovery to ANC ≥ 1,500/mm3 and platelets to ≥ 100,000/mm3, the dose 
level -1 will be administered (160 mg/m2). Discontinue dose if patients do not 
recover within ≤ 4 weeks.  If patient was already receiving Temozolomide at the -1 
dose level, reduce t o the -2 dose (128 mg/m2).  
 
**Upon recovery to ANC ≥ 1,500/mm3 and platelets to ≥ 100,000/mm3, the dose 
level -2 will be administered (128 mg/m2). Discontinue dose if patients do not 
   
 42 recover within ≤ 3 weeks. If patient was already receiving Temozolomide at the -2 
dose level, treatment should be discontinued.  
 
Non-hematologic Toxicity  
For non -hematologic toxicities, dose reductions of t emozolomide will be at the 
discretion of the investigator.  Dose -reductions should follow the Temozolomide 
Dose Level Tabl e above.  A maximum of  2 dose reductions can be performed.  
6.3 Capecitabine administration, storage, and toxicity management  
Capecitabine will be dosed at 750 mg/m2 PO BID for days [ADDRESS_54679] 500 mg.  Adjusted ideal 
body weight will be used for BSA calculations.   
Capecitabine is a fluoropyrimidine carbamate that is an orally active prodrug of 5 -
fluorouracil.  Normal cells, as well as tumor cells, metabolize 5 - fluorouracil into  5-fluoro -
2’deoxyuri dinemonophosphate (FdUMP) and 5 -fluorouridine triphosphate (FUTP). Both 
are metabolites that cause cell injury by [CONTACT_51735].  FdUMP and the folate 
factor, N5 -10-methylenetetrahydrofolate, bind to thymidylate synthase (TS)  to inhibit the 
formation of thymidylate. This deficiency of thymidylate causes cell cycle division to halt. 
This is because thymidylate is necessary for thymidine triphosphate production, which is 
essential for DNA synthesis.  FUTP works by [CONTACT_51736].  
Capecitabine  will be supplied by [CONTACT_8229]/[COMPANY_002] as the commercially available form of 
this medication.  
For further details and m olecule characteriza tion, see the Capecitabine  Investigator 
Brochure.  
6.3.1 Capecitabine Administration  
Capecitabine will be administered at an initial dose of 750 mg/m2 by [CONTACT_1966] t wice daily, 
on days 1 -14 of a 28 -day cycle.    
Capecitabine is supplied as b iconvex, oblong film -coated tablets, available as 150 mg 
tablets (light peach) and 500 mg tablets (peach).  Capecitabine is stored at 25  oC, with 
excursions permitted to 15 to 30 oC.   
Capecitabine  tablets should be swallowed with water within 30 minutes a fter a meal.  The 
calculated dose by [CONTACT_51737] (BSA) will be rounded down to allow doses using 
500 mg tablets.    
 
   
 43 6.3.2 Capecitabine Dose Modification and Toxicity Management  
Capecitabine will be initiated at 750 mg/m2 PO BID x 14 days on a 28 -day cycle.  
Two total dose reductions are permitted before cape citabine will be discontinued.    
  
   
 44 Hematologic Toxicities  
ANC (/ mm³)  Platelets (/ mm³) Modification  
<1500/mm3  AND/OR  < 100,000/mm3 Hold until ANC ≥ 1500/mm3 
and PLT ≥ 
100,000/mm3; 
resume at 20%  dose 
reduction  
≥ 1500/mm3 AND  ≥ 100,000/mm3 No dose modification  
Mucositis, Diahhrea, or Esophagitis   
Grade  Toxicities/Symptoms  Modification  
1 Mucositis,diarrhea, or 
esophagitis  No dose modification  
2 Diarrhea  No dose modification  
2 Mucositis or e sophagitis  Hold until < grade 1 ; 
resume at 20% dose 
reduction  
3 Diarrhea  Hold until < grade 1 
;resume at 20% dose 
reduction  
3/4 Mucositis or esophagitis  Hold until < grade 1; 
resume at 20% dose 
reduction  
 
Hand and Foot Rash  
Grade  Modification  
1 No dose  modification  
2 Hold until symptoms resolve to grade 0 or 1.  Resume at 
20% dose reduction.  
> 3 Hold until symptoms resolve to grade 0 or 1.  
Resume at 20% dose reduction.  
 
Non-hematologic Toxicity  
   
 45 For other non -hematologic toxicities, dose reductions o f capecitabine  will be at the 
discretion of the investigator.  A 20% dose reduction  should be performed with 
each subsequent reduction.  A maximum of 2 dose reductions can be performed.  
6.4 General Dos e Modifications  
All toxicity grades above  are described  using the NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0 .   
 
Dose reduction will be based on day 1 labratory values of each cycle.  
 
Dose reductions will be based on current dos e. If dose reduction is required, reduction 
is permanen t. Missed doses will not be made up.  
 
Dose will be modified for all drugs if there is a ≥ 5% change in patient’s weight while on 
study.  
 
If multiple toxicities are seen, the dose administered in a su bsequent cycle should be 
based on the most severe toxic ity experienced in the current cycle.  
 
AEs determined to be unrelated to study treatment will not require dose reduction.  
 
If toxicities have not resolved within ≤ [ADDRESS_54680] igator’s discretion for any adverse event with severity of grade [ADDRESS_54681] criteria, the patient can restart the original schedule of 
temozolomide, capecitabine, and bevacizumab at the investigator’s discretion.  
 
6.[ADDRESS_54682] been shown to increase by [CONTACT_3450] 20 -35% 
when given concurrently with antacids.  Therefore administration of capecitabine should 
be separated by [CONTACT_51738].  
Capecitabine increases the serum level of warfarin wi th concom itant administration.  
Therefore, a patient who takes both requires more frequent testing of INR and PT so the 
appropriate dose adjustment can be made.  
   
 [ADDRESS_54683] with CYP450 isoenzymes although extra 
care should be expressed when administering CYP2C9 substrates.  
6.5.2 Pre-medications  
Ondansetro n is requ ired as a premedication 30 minutes prior to temozolomide. 
Otherwise, anti-emetics, anxiolytics, and analgesics may be provided at physicians’ 
discretion.  
6.5.3  Supportive Care Guidelines  
Supportive treatment may include anti -emetics, antidiarrhe al medica tions, anti -pyretics, 
anti-histamines, analgesics, antibiotics, and others, such as blood products.  Patients who 
experience indigestion or gastroesophageal reflux symptoms may be treated with Proton 
Pump Inhibitors (PPIs) as well as H2 blockers a s clinica lly indicated.  
Blood products transfusions will be administered according to institutional guidelines. 
Plasma products, antibiotic and antifungal therapy will be administered on as needed on 
an individual case basis. Hematopoetic  growth factors wi ll be permitted for the 
management of anemia and/or neutropenia  per ASCO guidelines .  Patients will be 
permitted to receive appropriate supportive care measures as deemed necessary by [CONTACT_47806] .  
 
7.0 Clinical and Laboratory Ev aluations  
Cycle  Screen  1a 1b 2a 2b 3a 3b Follow Up  
(Every 6  
month + 1 
month ) Withdrawal 
of study 
treatmentg 
Dayd 0 1 15 1 15 1 15   
Informed consent  X         
Inclusion/exclusion 
criteria  X         
Medical history  
(including hormone 
functional status)  X X  X  X   X 
Physical examination  X X  X  X   X 
Performance Status  X X  X  X  Xe X 
Vital signs  X X X X X X X  X 
Hematology/chemistry  X X X X X X X  X 
Urinalysis or dipstickb X X  X  X   X 
Biomarkersc X X  X  X   X 
Pregnancy test  X         
   
 47 Cycle  Screen  1a 1b 2a 2b 3a 3b Follow Up  
(Every 6  
month + 1 
month ) Withdrawal 
of study 
treatmentg 
Dayd [ADDRESS_54684]  Xa     Xa  
Xf Xa 
Tolerability/AE reporting   X  X  X   X 
Concurrent medication  
(Somatostatin analogue 
only) h X X  X  X   X 
Bevacizumab (d1 + 15)   X X X X X X   
Capecitabine (d1 -14)  X  X  X    
Temozolomide (d10 -14)  X  X  X    
a- Measurement of tumor will be done at ba seline, every 3 cycles (end of cycle 3, 6, 9, etc.) and at withdrawal of study 
treatment  
b- Urinalysis  or dipstick  obtained at screening and at least every [ADDRESS_54685] day of each cycle, other hormone markers may be 
checked at the investigator’s discretion.  
d- Patients may be seen within a +/- 7 -days window of the assigned stud y visit.  
e- Survival follow up can be done by [CONTACT_33982]  
f- Till disease  progression  
g- If patient doesn’t want to be followed up.  
h- Start and stop dates and dose of somatostatin analogue (SSA) should be recorded. SSAs include short and long-acting  
Octreotide and Lanreotide.  
 
 
7.1 Pre-Treatment Evaluations  
• Screening visit to occur  ≤ 14 days prior to start date.  
• Vital signs, including blood pressure  
• Medical history, physical exam, and assessment of performance status  
• Functional status should be recorded as “Yes or No.”  Functional status is defined as 
elevated hormone biomarker with symptoms attributable to that hormone elevation 
(i.e. flushing or diarrhea associated with elevated serotonin or urine 5HIAA).  To be 
determined by t reating physician.  
• Blood: Complete blood count with differential, comprehensive metabolic panel, 
Chromogran in A, other neuroendocrine markers at the investigator’s discretion, and 
serum banked for future studies  (banked serum is mandatory ). 
• Urine:  
• Urinanalysis  (pH, specific gravity, glucose, protein, ketones and blood) OR urine 
dipstick are allowed .  Patients with 0, trace, or 1+ protein are eligible to enroll, if >= 
2+ must check 24h urine protein and must be < 1g to start study.   
• Pregnancy test i f female  
• Tissue: MGMT deficiency ( optional depending on availability, centrally tested at 
Stanford) .  See below in  section 7.3 for details.  
• Imaging:  
• Radiographic imaging, multi -phasic CT or MRI preferred, of measurable disease 
for assessment by [CONTACT_13407] (standard clinical care) .  This  must be done 
within 30  days of starting on study.  
   
 48 • CT Perfusion will be perfo rmed at baseline as a correlative study (Optional)  
 
7.[ADDRESS_54686] day of each cycle:  
• Medical history , physical exam, and assessment of performance status  
• Vital signs, including blood pressure  
• Blood: Complete blood count with  differential, comprehensive metabolic panel, 
Chromogranin A, and other neuroendocrine markers at the investigator’s discretion  
within 48 hours before treatment . 
• Chromogranin A and other neuroendocrine markers need not be re peated if it is done 
within last  3 weeks in case of delayed cycle or chemotherapy break.  
* Urine: Urinanalysis  (pH, specific gravity, glucose, protein, ketones and blood) OR 
urine dipstick are allowed .  Patients with 0, trace, or 1+ protein are eligible to get 
treated.  For the first occur rence of a 2+ value, 24 -hour urine confirmation is required.  
If the confirm ing 24 -hour urine is <2g/24h, subsequent 2+ urinalysis or dipstick values 
for that patient are acceptable.  
• Imaging:  
o Multi -phasic CT or MRI scans with measurement of target lesion s by [CONTACT_51739] [ADDRESS_54687] Pe rfusion will be performed after 2 wks and after 3 cycles as a correlative 
study. (Optional)  
 
7.[ADDRESS_54688] -Treatment Evaluations  
Upon patient withdrawal from study, every effort will be  undertaken to obtain the following  
(unless done within 4 weeks of study wit hdrawal) : 
• Medical history, physical exam, and assessment of performance status  
• Vital signs, including blood pressure  
• Blood: Complete blood count with differential, comprehensive me tabolic panel, 
Chromogranin A, and other neuroendocrine markers at the investigator’s discretion . 
• Imaging:  
• Multiphasic CT or MRI scans with measurement of target lesions by [CONTACT_51740] (OPTIONAL) as a correlative study will be perform ed if 
not done within 4 weeks prior to withdrawal from study.  
• Additional imaging will be at the investigator’s discretion per standard of care.  
 
7.4 Correlative Tissue/Blood Studies  
Representative tumor tissue samples will be used  in the studies described below.   The 
results of these studies are for the purposes of t he trial only and will not be returned to 
the site or reported to the patient.   Tissue for MGMT testing will be optional depending 
on availability and will not be an eligibility requirement.  
   
 49 Priority of  tissue use:  
1.   MGMT status by [CONTACT_4658]  
2.   MGMT status by [CONTACT_51741] (1:25 dilution; clone MT 3.1; Lab 
Vision), a biotinylated secondary antibody (mouse IgG),  and then avidin -horseradish 
peroxidase (Vectastain Elite ABC Kit; Vector Laboratories) according to the 
manufacturer’s instructions. Immunohistochemical MGMT expression will be scored as 
either ‘‘intact’’ or ‘‘deficient’’ in tumor cells using a prospectiv e classification scheme. 
Tumors will be scored as ‘‘intact ’’ when there is nuclear staining for MGMT in any tumor 
cells. Tumors will be scored as ‘‘deficient’’ when there is a complete absence of nuclear 
staining for MGMT in all tumor cells. Non -neoplastic  cells (lymphocytes, stromal cells, 
and endothelial cells)  served as an internal positive control in all tissue sections.   We 
will additionally use an external tissue array control slide with known negative tumor.  
The assay will be performed in a CLIA cert ified lab under the direction of Teri Longacre, 
MD at Stan ford University.  
 
Evaluation of MGMT status by [CONTACT_51742] -fixed paraffin embedded and then treated with bisulfite. 
Bisulfite treatment chemically converts unm ethylated cytosines to uracil but does not 
affect methylat ed cytosine. Two PCR reactions are then performed using primers 
corresponding to bisulfite modified (unmethylated) or unmodified (methylated) MGMT 
promoter sequence. The products of the PCR reaction  are analyzed by [CONTACT_51743].   Methylation -specific PCR performed on paraffin -embedded tissue 
specimens is dependent on tissue quality and quantity. It is important that there is little 
tissue necrosis since amplification could otherwise be  compromised. It is to be expected 
to frequently see ampli fication of both methylated and unmethylated MGMT promoter 
sequences in the same specimen, which likely represents heterogeneity among tumor 
cells and/or the presence in the specimen of non -neoplast ic cells. Presence of promoter 
methylation, which causes e pi[INVESTIGATOR_51686], a DNA repair gene 
on chromosome 10q26, is a positive predictive factor for chemotherapeutic response to 
alkylating agents.  The assay will be performed in a CLIA  certified lab under the direction 
of Iris Schrijver M.D a t Stanford University.  
 
Corrleative Specimen Submission Requirements  
Diagnostic material from previously collected tissue (core biopsy or surgical specimen 
preferred over FNA) must be submitted for optional laboratory research studies. 
Peripheral blood is to be submitted from consenting patients for future research studies.  
The IRB -approved consent must allow patients the option to provide specimens to for 
use in the optional laboratory studies and f or undefined future research.    
 
Specimen Preparation Guid elines  
Tissue Samples  
The following materials are to be submitted:  
   
 50 • One representative diagnostic formalin -fixed paraffin -embedded tumor block, 
core biopsy or surgical specimen preferred.     
• NOTE:  If a block is unavailable for submission, submit the followi ng: 
o For MGMT IHC: 3 unstained slides, 4 microns thick  
o For MGMT promoter methylation: 3 unstained slides, 20 microns thick  
 
Peripheral Blood, ACD or EDTA  
• Blood specimens will be collected during rout ine care on cycle 1 day 1 using three 
tubes, for whole blood (6 cc purple top), serum (6cc red top) and plasma (6 cc 
purple top)  
• All blood samples will be processed within [ADDRESS_54689] 30 minutes prior to 
centrifugation.  
• For serum and plasma, samples will be spun in a centrifuge for 15 minutes at 
3000 rpm at room temperature.  After spi[INVESTIGATOR_51687] r each . One tube of whole blood will be stored without 
processing.  
• These samples may be stored at the individual sites until the time of analysis in a 
-80C freezer per institutional protocols at Stanford, UC SF and Moffitt.  
 
Pathology Contact [CONTACT_51744] s amples should be labeled:  
“For Kunz Ph II Trial Tem/Cape/Bev central MGMT review”  
 
Tissue samples should be mailed to:  
Pamela Kunz, MD  
Stanford Cancer Institute  
[ADDRESS_54690], CA 9430 5-5826  
[EMAIL_971]  
 
 
Pathology samples will be distributed by [INVESTIGATOR_124]. Kunz and her team to the appropriate 
investigators as follows to:  
 
For MGMT immunohistochemistry:  
Teri Longacre, M.D.  
Professor of Patholog y 
Stanford University School of Medicine  
Department of Pathology  
[ADDRESS_54691], CA [ZIP_CODE]  
Phone : xxx-xxx-xxxx 
Email: cccccccccccccccccc  
  
   
 51   
For MGMT promoter methylation:  
Iris Schrijver M. D.  
Associate Professor of Pathology  
Stanford University School of Medicine  
Department of Pathology / Molecular Pathology  
[ADDRESS_54692], CA [ZIP_CODE] -5627  
Phone:  
Fax:  
Email:    
  
8.[ADDRESS_54693] Discontinuation  
Patients will continue on treatment un til one of the following occurs:  
1. Patient chooses to withdraw from study  
2. Unacceptable toxicity occurs  
3. Evidence of progressive disease by [CONTACT_51745] :  
1. Patient removes consent  
2. Completion of protocol treatment  
3. Patient relapses or progresses to a point that additional or alternative therapy is 
indicat ed 
4. The patient may withdraw from the study at any time for any reason.  
5. Patient is now excluded  
6. Patient fails to meet scheduled clinical visits lea ding to a sufficiently incomplete 
dataset for analysis  
7. Patient is diagnosed with a new tumor requiring treatme nt  
8. The patient has a clinically significant treatment adverse event as determined by 
[CONTACT_079].  
9. The development of circumstances  which prevent study evaluations/visits  
10. The patient requires a dose level of <100 mg/m2/day for 5 days for TEMODAR.  
11. Evidence of disease progression prior to completion of 3 cycles  
12. Patient is non -compliant with study medication  
13. Grade 4 hypertension or Grade  3 hypertension not controlled with medication  
14. Nephrotic syndrome  
15. Grade ≥ 2 pulmonary or CNS hemorrhage; an y Grade 4 hemorrhage  
   
 52 16. Symptomatic Grade 4 venous thromboembolic event (for lung protocols: any 
venous thromboembolic event requiring full dose warfari n or equivalent (i.e., 
unfractionated or low molecular weight heparin)  
17. Any grade arterial thromboembolic e vent 
18. Grade 4 congestive heart failure  
19. Gastrointestinal perforation  
20. Tracheoesophageal fistula (any grade) or Grade [ADDRESS_54694] to continue 
therapy  
25. All Grade 4 events thought to be related to bevacizu mab by [CONTACT_093]  
26. Becomes pregnant  
27. Withdrawal of consent  
28. Development of a serious intercurrent medical condition or need for concomitant 
treatm ent that precludes further participation in the trial  
29. Progressive disease  
NOTE: Patients who have an ongoin g drug-related Grade 4 or serious adverse event at 
the time of discontinuation from study treatment will continue to be followed until 
resolution of the event or until the event is considered irreversible . 
9.0 Study Follow Up  
After study treatment discontinued patients will be followed every 6 months till death for 
disease progression and survival.  (See section 7.0)   Discontinuation of the study will b e 
considered  after review of the data by [CONTACT_51746]:  
• Major toxicity ( i.e. life -threatening hemorrhage) attributable to study treatment.  
• Determination by [CONTACT_51747] 1 above.  
10.0 Statistical Methods  
10.1 Determination of Sample size  
A sample size of 30 patients would give 80% power to reject the null RR of 40% if the true 
response rate (RR) is 65% or higher. The null hypothes is is based on a prospective phase 
II study conducted by [CONTACT_51711], et al evaluating t he efficacy of temozolomide and 
thalidomide1.  In this study, 29 patients with mixe d metastatic NETs were treated with 
temozolomide 150 mg/m2 for 7 days every other week and thalidomide at doses of 50 -
400 mg daily.  The overall radiographic response was 25% (45% in patients with 
   
 53 pancreatic NETs).  The alternative hypothesis is based on t he more recent retrospective 
study in patients with pancreatic NETs reported by [CONTACT_51712], et al in which 30 patients 
were treated with capecitabine (750mg/m2 twice daily, days 1 -14) and temozolomide (200 
mg/m2 once daily, days 10 -14) every 28 days; the RR  was 70%6.  RR is defined as the 
proportion of patients with complete response + partial response (CR+PR) based on a 
patient’s best response.  
 
The study will be stopped if there are excessive toxicities associated with the study 
regimen.   An interim analysis for safety will be performed after the first [ADDRESS_54695] one dose of protocol therapy will be 
included in the analyses.   Specifically, we will stop the study and re -evaluate the 
approach if it is  determined that ≥[ADDRESS_54696] 10 patients experience grade 3/4 non -
hematologic treatment -related adverse events despi[INVESTIGATOR_51688]  
(excluding alopecia) , or grade 4 hematologic treatment -related adverse events despi[INVESTIGATOR_51689], or other excessive toxicity resulting in death or removal from 
study (as outlined in Section 6.0). The patients included in these analyses will be 
followed without stoppi[INVESTIGATOR_51690].    
10.2 Planned Efficacy Evaluations  
Primary Efficacy Variables  
• RR and AEs  
Secondary Efficacy Variables  
• PFS and OS  
• Biomarkers  
• MGMT  
• CT perfusion (if performed)  
Efficacy Assessment using Response Eval uation Criteria in Solid Tumors 
Guideline (RECIST v 1.1)29  
 Definitions : At baseline, tumor lesions/lymph nodes will be categorized measurable or 
non-measurable as follows:  
 
Measurable : 
• Tumor lesions: Must be accurately measured in at least one dimension (longest 
diameter in the plane of measurement is to be recorded) with a minimum size of:  
o 10mm by [CONTACT_3610] (CT scan  slice thickness no greater than 5 mm).  
o 10mm caliper measurement by [CONTACT_51748] (lesions which cannot be 
accurately measured with calipers should be recorded as non -
measurable).  
o 20mm by [CONTACT_13190] X -ray. 
• Malignant lymph nodes: To be considered pathologically enlarged and 
measurable, a lymph node must be ≥15mm in short axis when a ssessed by [CONTACT_4654] 
   
 54 scan (CT scan slice thickness recommended to be no greater than 5 mm). At 
baseline and in follow -up, only the short axis will be measured and followed.  
 
Non-measurable:  
• All other lesions, including small lesions (longest diameter <10mm or pa thological 
lymph nodes with P10 to <15mm short axis) as well as truly non -measurable 
lesions. Lesions considered truly non -measurable include: leptomeningeal 
disease, ascites, pleural or pericardial effusion, inflammatory breast disease, 
lymphangitic invol vement of skin or lung, abdominal masses/abdominal 
organomegaly identified by [CONTACT_51749] . 
 
Specifications by [CONTACT_51750]:  
• All measurements should be recorded in metric no tation, using calipers if 
clinically assessed. All baseline evaluations should be performed as close as 
possible to the treatment start and never more than 4 weeks before the 
beginnin g of the treatment.  
 
Method of assessment  
• The same method of assessment a nd the same technique should be used to 
characterize each identified and reported lesion at baseline and during follow -up. 
Imaging based evaluation should always be done rather than c linical examination 
unless the lesion(s) being followed cannot be imaged but are assessable by 
[CONTACT_461].  
 
• Clinical lesions: Clinical lesions will only be considered measurable when they 
are superficial and ≥10mm diameter as assessed using calipers (e. g. skin 
nodules). For the case of skin lesions, documentation by [CONTACT_51751] p hotography 
including a ruler to estimate the size of the lesion is suggested. As noted above, 
when lesions can be evaluated by [CONTACT_51752], imaging 
evaluation shoul d be undertaken since it is more objective and may also be 
reviewed at th e end of the study.  
 
• Chest X -ray: Chest CT is preferred over chest X -ray, particularly when 
progression is an important endpoint, since CT is more sensitive than X -ray, 
particularly i n identifying new lesions. However, lesions on chest X -ray may be 
conside red measurable if they are clearly defined and surrounded by [CONTACT_14238].  
 
• CT, MRI: CT is the best currently available and reproducible method to measure 
lesions selected f or respon se assessment, but MRI is acceptable. This guideline 
has defined measurabi lity of lesions on CT scan based on the assumption that 
CT slice thickness is 5mm or less.  
 
   
 55 • Ultrasound: Ultrasound is not useful in assessment of lesion size and should not 
be used a s a method of measurement.  
 
• Endoscopy, laparoscopy: The utilization of th ese techniques for objective tumor 
evaluation is not advised.  
 
• Tumor markers: Tumor markers alone cannot be used to assess objective tumor 
response. If markers are initially above th e upper normal limit, however, they 
must normalize for a patient to be co nsidered in complete response.  
 
• Cytology, histology: These techniques can be used to differentiate between PR 
and CR in rare cases if required by [CONTACT_990].  
 
Tumor response evaluation  
 Baseline documentation of ‘target’ and ‘non -target’ lesions  
• When more t han one measurable lesion is present at baseline all lesions up to a 
maximum of five lesions total (and a maximum of two lesions per organ) 
representative of all involved or gans should be identified as target lesions and 
will be recorded and measured at ba seline.  
 
• Target lesions should be selected on the basis of their size (lesions with the 
longest diameter), be representative of all involved organs, but in addition should 
be those that lend themselves to reproducible repeated measurements.  
 
• A sum of the diameters (longest for non -nodal lesions, short axis for nodal 
lesions) for all target lesions will be calculated and reported as the baseline sum 
diameters. If lymph nodes are to be included in the sum, then as noted above, 
only the short axis is added in to the sum. The baseline sum diameters will be 
used as reference to further characterize any objective tumor regression in the 
measurable dimension of the disease.  
 
 Respons e criteria  
• Complete Response (CR): Disappearance of all target lesions. Any patholo gical 
lymph nodes (whether target or non -target) must have reduction in short axis to 
<10 mm.  
 
• Partial Response (PR): At least a 30% decrease in the sum of diameters of targ et 
lesions, taking as reference the baseline sum diameters.   
 
• Progressive Disease ( PD): At least a 20% increase in the sum of diameters of 
target lesions, taking as reference the smallest sum on study (this includes the 
baseline sum if that is the smallest on study). In addition to the relative increase 
of 20%, the sum must also demonstr ate an absolute increase of at least 5 mm. 
(Note: the appearance of one or more new lesions is also considered 
progression).  
 
   
 56 • Stable Disease (SD): Neither sufficient  shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference  the smallest sumdiameters while 
on study.   
 
For other details and special circumstances of the RECIST guidelines refer directly to 
reference.  
 
Time point response: patients with target (+/ - non-target lesions)  disease  
 
Target lesions  Non-target lesions  New lesions  Overall response  
CR CR No CR 
CR Non-CR/non -PD No PR 
CR Not evaluated  No PR 
PR Non-PD or not all 
evaluated  No PR 
SD Non-PD or not all 
evaluated  No SD 
Not all evaluated  Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
CR = complete response, PR = partial response, SD = stable disease, PD = progressive 
disease, and NE = inevaluable  
 
Definitions of Other Efficacy Markers  
Radiographic Response Rate (RR ): The proportion of patients with complete response 
+ partial  response ( CR+PR) based on a patient’s best response.  
 
Overall Survival (OS):   Time from the date of enrollment to the date of death due to any 
cause or the last date the patient was known to be alive (censored observation) at the 
date of data cutoff for the final an alysis  
Time to Progression (TTP):   Time from the date of enrollmen t to the date of the first 
observation of documented disease progression or death to due cancer  
Progression -Free Survival (PFS):  Duration of time from start of treatment to time of 
documente d progression or death.  
 
NOTE: Imaging will be performed and revi ewed at the separate sites; a central radiology 
review will not be performed.  
 
10.3 Plan of analysis  
The proportion of RR (CR+PR) will be estimated along with a one -sided lower 95% exact 
confidence bound to allow an informal assessment of the null hypothesis (RR=40%) 
based on binomial probabilities; assessment will be regarded as informal since we do not 
expect to be able to adjust for differences in clinical and demographic in the comparator  
study.  Proportions will be estimated along with 95% exact confidence intervals.  Time to 
   
 57 event data will be evaluated using Kaplan -Meier estimates with 95% confidenc e intervals 
at multiples of 12 months based on Greenwood’s formula with a log transform.  
Confidence intervals for median times to event, if relevant, will be constructed using the 
method of Brookmeyer and Crowley. Biomarkers will be summarized using media ns and 
interquartile ranges; changes in biomarkers will be assessed using Wilcoxon’s sign ed 
rank test. Adverse events will be tabulated by [CONTACT_51753].  Patient clinical 
and demographic characteristics will be reported with the appropriate su mmary statistic 
(mean, range, proportion etc.)  Progression -free survival (PFS) and overal l survival (OS) 
will be evaluated using Kaplan -Meier analysis.  For PFS analyses, patients will be 
censored at time last known alive if no progression has occurred.  De-identified patient 
data will be used for all analys es. 
 
11.0 Safety Reporting of Adverse  Events   
11.1  Genentech -specific Safety Reporting  (for both capecitabine and 
bevacizumab ) 
Assessment of Safety  
Specification of Safety Variables  
Safety assessments will consist of monitoring and reporting adverse events (AEs) and 
serious adverse events ( SAEs) that are considered related to capecitabine or 
bevacizumab , all events of death, and any study specific issue of concern.  
Adverse Events  
An A E is any unfavorable and unintended sign, symptom, or disease temporally 
associated with the use of an invest igational medicinal product (IMP) or other protocol -
imposed intervention, regardless of attribution.  
 
This includes the following:  
• AEs not previous ly observed in the subject that emerge during the protocol -
specified AE reporting period, including signs or symptoms associated with 
advanced pancreatic neuroendocrine tumors  that were not present prior to the 
AE reporting period.  
• Complications that occur  as a result of protocol -mandated interventions (e.g., 
invasive procedures such as cardiac catheterizations).  
 
If applicable, AEs that occur prior to assignment of study treatment associated with 
medication washout, no treatment run -in, or other protocol -mandated intervention.  
 
Preexisting medical conditions (other than the condition being studied) judged by [CONTACT_51754] -specified AE reporting period.  
   
 58 Serious Adverse E vents  
An AE should be classified as an SAE if the following criteria are met:  
• It results in death (i.e., the AE actually causes or leads to death).  
• It is life threatening (i.e.,  the AE, in the view of the investigator, places the subject 
at immediate risk of death. It does not include an AE that, had it occurred in a 
more severe form, might have caused death.).  
• It requires or prolongs inpatient hospi[INVESTIGATOR_059].  
• It results in persistent or significant disability/incapacity (i.e., the AE results in 
substantial disruption of the subject’s ability to conduct normal life functions).  
• It results in a congenital anomaly/b irth defect in a neonate/infant born to a mother 
exposed to the IMP.  
• It is considered a significant medical event by [CONTACT_51755] (e.g., may jeopardize the subject or may require medical/surgical 
intervention to prevent one of  the outcomes listed above).  
Methods and Timing for Assessing AND Recording Safety variables  
The investigator is responsible for ensuring  that all AEs and SAEs that are observed or 
reported during the study, are collected and reported to the FDA, appropria te IRB(s), 
and Genentech, Inc. in accordance with CFR 312.32 (IND Safety Reports).  
Adverse Event Reporting Period  
The study period during which all AEs and SAEs must be reported begins after informed 
consent is obtained and initiation of study treatment a nd ends [ADDRESS_54697] 
administration of study treatment or study discontinuation/termination, whichever is 
earlier. Aft er this period, investigators should only report SAEs that are attributed to 
prior study treatment.  
Assessment of Adverse Ev ents 
All AEs and SAEs whether volunteered by [CONTACT_423], discovered by [CONTACT_13661], or detected through phys ical examination, laboratory test, or other 
means will be reported appropriately. Each reported AE or SAE will be described by [CONTACT_14215] (i.e.,  start and end dates), regulatory seriousness criteria if applicable, 
suspected relationship to the {study dru g} (see following guidance), and actions taken.  
 
To ensure consistency of AE and SAE causality assessments, investigators sh ould 
apply the following general guideline:  
Yes 
There is a plausible temporal relationship between the onset of the AE and 
administr ation of the {study drug}, and the AE cannot be readily explained by [CONTACT_1560]’s clinical state, intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the AE 
follows a known pattern of response to the {study drug}; and/or the AE abates or 
resolves upon discontinuation of the {study drug} or dose reduction and, if applicable, 
reappears upon re -challenge.  
No 
   
 59 Evidence exists th at the AE has an etiology other than the {study drug} (e.g., preexisting 
medical condition, underlying disease, intercurrent illness , or concomitant medication); 
and/or the AE has no plausible temporal relationship to {study drug} administration (e.g., 
cancer diagnosed [ADDRESS_54698] dose of study drug).  
 
Expected adverse events are those adverse events that are listed or character ized in 
the Package Insert or current Investigator Brochure.  
 
Unexpected adverse events are those not listed in the Package  Insert (P.I.) or current 
Investigator Brochure (I.B.) or not identified. This includes adverse events for which the 
specificity or severity is not consistent with the description in the P.I. or I.B. For 
example, under this definition, hepatic necrosis wou ld be unexpected if the P.I. or I.B. 
only referred to elevated hepatic enzymes or hepatitis.  
Procedures for Eliciting, Recording, an d Reporting Adverse Events  
Eliciting Adverse Events  
A consistent methodology for eliciting AEs at all subject evaluation tim epoints should be 
adopted. Examples of non -directive questions include:  
• “How have you felt since your last clinical visit?”  
• “Have y ou had any new or changed health problems since you were last here?”  
Specific Instructions for Recording Adverse Events  
Investigators should use correct medical terminology/concepts when reporting AEs or 
SAEs. Avoid colloquialisms and abbreviations.  
 
a. Diagnosis vs. Signs and Symptoms  
If known at the time of reporting, a diagnosis should be reported rather than individual 
signs and symptoms (e.g., record only liver failure or hepatitis rather than jaundice, 
asterixis, and elevated tran saminases). However, if a constellation of signs and/or 
symptoms cannot be medically characterized as a single diagnosis or syndrome at the 
time of reporting, it is ok to report the information that is currently available. If a 
diagnosis is subsequently es tablished, it should be reported as follow -up information.  
 
b. Deaths  
All deaths that occur during the protocol -specified AE reporting period (s ee Section 
11.1), regardless of attribution, will be reported to the appropriate parties. When 
recording a death , the event or condition that caused or contributed to the fatal outcome 
should be reported as the single medical concept. If the cause of death  is unknown and 
cannot be ascertained at the time of reporting, report “Unexplained Death”.  
 
c. Preexisting Medi cal Conditions  
A preexisting medical condition is one that is present at the start of the study. Such 
conditions should be reported as medical a nd surgical history. A preexisting medical 
condition should be re -assessed throughout the trial and reported as an AE or SAE only 
   
 60 if the frequency, severity, or character of  the condition worsens during the study. When 
reporting such events, it is importan t to convey the concept that the preexisting 
condition has changed by [CONTACT_9672] (e.g.,  “more frequent 
headaches”).  
 
d. Hospi[INVESTIGATOR_51691]. If a subject is hospi[INVESTIGATOR_9615] a medical 
or surgical  procedure as a result of an AE, the event responsible for the procedure, not 
the procedure itself, should be reported as the SAE. For example, if a subject is 
hospi[INVESTIGATOR_15428], record the heart condition that 
necessitated th e by[CONTACT_13664].  
 
Hospi[INVESTIGATOR_15429]:  
• Hospi[INVESTIGATOR_51692]  
• Hospi[INVESTIGATOR_13266] r equired to allow efficacy 
measurement for the study or  
• Hospi[INVESTIGATOR_51693].  
•  
e. Pregnancy  
If a female subject becomes pregnant while receiving investigational t herapy or with in 
[ADDRESS_54699] dose of study drug, a report should be completed and 
expeditiously submitted to the Genentech, Inc. Follow -up to obtai n the outcome of the 
pregnancy should also occur. Abortion, whether accidental, therapeutic, or 
spontaneous, should always be classified as serious, and expeditiously reported as an 
SAE. Similarly, any congenital anomaly/birth defect in a child born to a f emale subject 
exposed to the {study drug} should be reported as an SAE.  
 
f. Post -Study Adverse E vents  
The investigator should expeditiously report any SAE occurring after a subject has 
completed or discontinued study participation if attributed to prior {s tudy drug} exposure. 
If the investigator should become aware of the development of cancer or a c ongenital 
anomaly in a subsequently conceived offspring of a female subject who participated in 
the study, this should be reported as an SAE.  
 
g. SAE Reporting  
Investigators must report all SAEs to Genentech within the timelines described below. 
The completed Medwatch/case report should be faxed immediately upon completion to 
Genentech Drug Safety at:  
 
(XXX-xxx-xxxx  
OR 
   
 61 (xxx) xxx -xxxx  
 
• Relevant follow -up informat ion should be submitted to Genentech Drug Safety as 
soon as it becomes available.  
• Serious AE reports that are related to capecitabine or bevacizumab  will be 
transmitted to Genentech within fifteen (15) calendar days of the Awareness 
Date.  
• Serious AE report s that are unrelated to capecitabine or bevacizumab  will be 
transmitted to Genentech withi n thirty (30) calendar days of the Awareness Date.  
• Additional Reporting Requirements to Genentech include the following:  
• Any reports of pregnancy following the start of administration with the 
capecitabine or bevacizumab  will be transmitted to Genentech wi thin thirty (30) 
calendar days of the Awareness Date.  
• All Non -serious Adverse Events originating from the Study will be forwarded, at 
most, on a quarterly report to Genentech.  
 
Note: Investigators should also report events to their IRB as required.  
MedWat ch 3500A Reporting Guidelines  
In addition to completing appropriate patient demographic and suspect medication 
information, the report should include the following in formation within the Event 
Description (section 5) of the MedWatch 3500A form:  
• Protocol de scription (and number, if assigned)  
• Description of event, severity, treatment, and outcome if known  
• Supportive laboratory results and diagnostics  
• Investigator’s asses sment of the relationship of the adverse event to each 
investigational product and suspect  medication  
Follow -up Information  
Additional information may be added to a previously submitted report by [CONTACT_51756]:  
• Adding to the original MedWatc h 3500A report and submitting it as follow -up 
• Adding supplemental summary information and submitting it as follow -up with the 
original MedWatch 3500A form  
• Summarizing new information and faxing it with a cover letter including patient 
identifiers (i.e. D. O.B. initial, patient number), protocol description and number, if 
assigned, brief adverse  event description, and notation that additional or follow -
up information is being submitted (The patient identifiers are important so that the 
new information is add ed to the correct initial report)  
Occasionally Genentech may contact [CONTACT_15483], 
clarification, or current status of the patient for whom and adverse event was reported. 
For questions regarding SAE reporting, you may contact [CONTACT_3433] e Genentech Drug Safety 
representative noted above or the MSL assigned to the study. R elevant follow -up 
information should be submitted to Genentech Drug Safety as soon as it becomes 
available and/or upon request.  
 
   
 62 MedWatch 3500A (Mandatory Reporting) form  is available at  
http://www. fda.gov/medwatch/getforms.html   
Additional Reporting Requirements for IND Holders  
For Investigator -Sponsored IND Studies, some additional reporting requirements for the 
FDA apply in accordance with the guidance set forth in 21 CFR § 600.80.  
 
Events meeting the following criteria need to be submitted to the Food and Drug 
Administration (FDA) as expedited IND Safety Reports according to the following 
guidance and timelines:  
 
7 Calendar Day Telephone or Fax Report:  
The Investigator is required to notify  the FDA of any fatal or life -threatening adverse 
event that is unexpected and assessed by [CONTACT_51757] . An unexpected adverse event is one that is not 
already described in the capecitabi ne or bevacizumab  Investigator Brochure s. Such 
reports are to be telephoned or faxed to the FDA and Genentech within [ADDRESS_54700] learning of the event.  
 
15 Calendar  Day Written Report  
The Investigator is also required to notify the FDA and all  participating investigators, in a 
written IND Safety Report, of any serious, unexpected AE that is considered reasonably 
or possibly related to the use of capecitabine or bevac izumab  .An unexpected adverse 
event is one that is not already described in the  capecitabine or bevacizumab  
investigator brochure s. 
 
Written IND Safety reports should include an Analysis of Similar Events in accordance 
with regulation 21 CFR § 312.32. All safety reports previously filed by [CONTACT_51758], similar reports commented on.  
 
Written IND safety reports with Analysis of Simila r Events are to be submitted to the 
FDA, Genentech, and all participating inves tigators within [ADDRESS_54701] 
learning of the event. The FDA prefers these reports on a Medwatch 3500 form, but 
alternative formats are acceptable (e.g., summary let ter). 
 
FDA fax number for IND Safety Reports:  
Fax: 1 (800) FDA [ADDRESS_54702] also 
be faxed to Genentech Drug Safety:  
Fax: (  
   
 63  
AND  to the Site IRB:  
Stanford IRB / Research Compliance Office  
[ADDRESS_54703], [Mail Code: 5579]  
Palo Alto, CA [ZIP_CODE]  
Fax: x 
 
AND to Stanford  (for subsites UCSF and Moffitt) : 
 
Study Coordination Center/Principal Investigator  
[INVESTIGATOR_51694], MD  
Stanford Cancer Center  
[ADDRESS_54704], CA [ZIP_CODE] -5826 
x 
[EMAIL_971]  
 
For questions related to safety reporting, please contact [CONTACT_51759]:  
x 
IND Annual Reports  
Copi[INVESTIGATOR_15435]:  
All IND annual reports s ubmitted to the FDA by [CONTACT_1034] -Investigator should be 
copi[INVESTIGATOR_38269]. Copie s of such reports should be faxed to Genentech Drug 
Safety:  
 
x 
   
 64 Study Close -Out 
Any study report submitted to the FDA by [CONTACT_1034] -Investigator should be copi[INVESTIGATOR_15436]. This includes all IND annual reports and the Clinical Study Report (final 
study  report). Additionally, any literature articles that are a result of the study should be 
sent to Genentech. Copi[INVESTIGATOR_51695] d be mailed to the assigned Clinical 
Operations contact [INVESTIGATOR_25810]:  
 
Avastin Protocols  
Email: avastin -[EMAIL_973]  
Fax : xxxxxxxxxxx  
11.2  [COMPANY_006] Safety R eporting  
Follow same AE and SAE definitions as above.  
 
For [COMPANY_006], a ll SAEs should be recorded on a MedWatch 3500a Form and faxed to : 
 
[COMPANY_006]  (Attn: Worldwide Product Safety; FAX 215 993 -1220) must be provided with copi[INVESTIGATOR_51696], within two working days regardless of drug 
relationship.   Any pregnancy occurring in association with use of a [COMPANY_006] Product must 
also be reported to [COMPANY_006] (Attn: Worldwide Product Safety; FAX x).   
 
AND:  
 
Stanford IRB / Research Compliance Office  
[ADDRESS_54705], [Mail Code: 5579]  
Palo Alto, CA [ZIP_CODE]  
Fax : xxxxxxxxxx  
 
AND  (for subsites UCSF and Moffitt) : 
 
Study Coordination Center/Principal Investigator  
[INVESTIGATOR_51694], MD  
Stanford Cancer Center  
[ADDRESS_54706], CA [ZIP_CODE] -5826  
xxxxxxxxxxx ) 
[EMAIL_971]  
 
[COMPANY_006] follow -up period.  Patients will be followed for [ADDRESS_54707] been taken 
off trial regardless of causality.  
 
12.0 Retention of Records  
Research data will be recorded on study -specific Case Report Forms (CRFs) using a 
unique patient number for each patient to assure patient confidentiality. Data from 
source documents are used to transcribe critical protocol data on CRFs. Source 
   
 [ADDRESS_54708] 
protection and restricted access to computers (i.e., locked offices).  
13.[ADDRESS_54709] and/or 
clinical histories. Stanford will perform twice yearly on  site audits of source documents.  
Data detailed in the research case report forms includes the nature and severity of all 
toxicities, which are also reported as described above. All inve stigators on the protocol 
have received formal training in the ethical  conduct of human research. Institutional 
support of trial monitoring is provided in accordance with the Stanford University  
Institutional Data and Safety Monitoring Plan. Under the prov isions of this plan, the 
Stanford  Research Trials Office coordinates m onitoring for data accuracy and compliance 
by [CONTACT_51760], contract research organizations, or Stanford employees unaffiliated with 
the conduct of the study. Independent monitoring visit s occur at specified intervals 
determined by [CONTACT_51761] o f the study and the findings of previous visits. In 
addition, protocols are reviewed at least annually by [CONTACT_51762] (DS MC) and the Institutional Review Boa rd (IRB). The Stanford IRB reviews 
the study progress and safety infor mation to assess continued acceptability of the risk -
benefit ratio for huma n subjects. Approval of the IRB is necessary to continue the study. 
The trial will comply with the standard gui delines set forth by [CONTACT_51763]  (Scient ific Review Committee, IRB , DSMC) and other state and federal 
guidelines.  
 
To ensure trial -wide data and safety monitoring, the Principal Investigator [INVESTIGATOR_51697], 
and disseminating that information to the appropriate Consortium committees. The 
   
 66 Principal investigator  [INVESTIGATOR_51698], data accuracy and completeness, and full and timely 
reporting of safety data at outside sites. Written agreements will be obtained from all 
participating sites acknowledging their responsibilities for data and adverse event 
report ing and agreement to provide records, files, case report forms or any other 
documents to verify compliance.  
14.0 Ethical and Regulatory Co nsiderations  
General: Stanford will be the coordinating institution.  As such, all Case Report Forms 
(CRFs) will be re viewed by [CONTACT_51764].  Imaging will be 
reviewed separately at each site; a central review will not occur.  
 
Institutional Review Board  
In accordance with federal regulations (21 CFR 312.66), an Institutional Review Board 
(IRB) at Stanford  that complies with regulations in [ADDRESS_54710] review and approve 
this protocol and the informed consent form prior to initiation of the study.  
 
Independent Ethics Commi ttees/Institutional Review Board  
This protocol and the informed consent wil l be approved by [CONTACT_51765]. The 
Principal Investigator [INVESTIGATOR_51699] t o implementation. The Principal 
Investigator [INVESTIGATOR_51700] d of any significant adverse reactions, and any 
protocol exceptions or deviations. Records of all study review and approval documents 
must be kept on file by [CONTACT_51766]. The IRB will receive notification of the termination of the 
study.  
 
Consent  
The Principal Investigator [INVESTIGATOR_51701], 
duration,  and purpose of the study and possible consequences of treatment. Patients 
must also be informed that they may withdraw from the study at any time and for any 
reason without jeopardizing their future treatment. In accordance with federal regulations 
(21 CF R 50), all patients enrolled in the study must sign the IRB -approved consen t form.  
 
Clinical Trials Database and Results Registration   
The principal investigator [INVESTIGATOR_51702].clinicaltrials.gov, the US 
National Library of Medici ne website prior to initiation of the study. This website provides 
regularl y updated information about US government and privately supported clinical 
research in human volunteers. In addition, the investigator will make the results of the 
study publicly ac cessible by [CONTACT_51767].clinicaltrials.gov . 
 
Monitoring and Reporting Guidelines  
Investigators will conduct continuous review of data and patient safety at weekly study 
group or site committee meetings where the results of each patient’s data and stat us are 
discussed and the discussion is documented in the minutes. The discussion will include 
   
 67 any toxicity from temozolomide treatment including dose de -escalations if they were 
required. Quarterly summaries will be submitted to the DSMC for review. All AE ’s and 
SAE’s from temozolomide would have been entered into the Stanford Comprehensive  
Cancer Center CTMS database. The study coordinator will keep a log of subject(s) 
temozolomide treatment.  
 
Premature Closure of the Study  
This study may be prematurely t erminated, if in the opi[INVESTIGATOR_871] , 
Genentech  or [COMPANY_006], there is suffici ent reasonable cause.  Written notification 
documenting the reason for study termination will be provided  by [CONTACT_51272].   
Circumstances that may warrant termi nation include, but are not limited to:  
• Determination of unexpected, significant, or u nacceptable risk to patients  
• Failure to enter patients at an acceptable rate  
• Insufficient adherence to protocol requirements  
• Insufficient complete and/or evaluable data  
• Plans to modify, suspend or discontinue the development of the drug  
Should the study be  closed prematurely, all study drugs  must be returned to Genentech 
or [COMPANY_006] . 
 
Good Clinical Practice  
The study will be conducted in accordance with the International Conf erence on 
Harmonisation (ICH) for Good Clinical Practice (GCP) and the appropriate reg ulatory 
requirement(s).  The investigator will be thoroughly familiar with the appropriate use of 
the drug as described in the protocol and Investigator’s Brochure.  Esse ntial clinical 
documents will be maintained to demonstrate the validity of the study a nd the integrity of 
the data collected.  Master files should be established at the beginning of the study, 
maintained for the duration of the study and retained according  to the appropriate 
regulations.   
 
Ethical Considerations  
The study will be conducted in accordance with ethical principles founded in the 
Declaration of Helsinki .  The IRB/IEC will review all appropriate study documentation in 
order to safeguard the righ ts, safety and well -being of the patients.  The study will only be 
conducted after FHCRC IRB/IEC approval has been obtained.  The protocol, 
Investigator’s Brochure, informed consent, advertisements (if applicable), written 
information given to the patients  (including diary cards), safety updates, annual progress 
reports, and any re visions to these documents will be provided to the IRB/IEC by [CONTACT_1275].  The investigator, Genentech and [COMPANY_006]  will review informed consent 
documents prior to IRB/IEC subm ission.  
 
Patient Information and Informed Consent  
After the study has been f ully explained, written informed consent will be obtained from 
either the patient or his/her guardian or legal representative prior to study participation.  
The method of obtainin g and documenting the informed consent and the contents of the 
consent will c omply with ICH -GCP and all applicable regulatory requirement(s).  
 
   
 68 Patient Confidentiality  
In order to maintain patient privacy, all data capture records, drug accountability recor ds, 
study reports and communications will identify the patient by [CONTACT_51768]. The patient’s confidentiality will be maintained and will not be made 
publicly available to the extent permitted by [CONTACT_51769]. 
 
Protocol Compliance  
The investigator will conduct the study in compliance with the protocol given 
approval/favorable opi[INVESTIGATOR_1686]/IEC and the appropriate regulatory authority(ies).  
Changes to the protocol will require approval from Genentech a nd [COMPANY_006], and written 
IRB/IEC approval/favorable opi[INVESTIGATOR_51703], except when the modification 
is needed to eliminate an immediate hazard(s) to patients.  The IRB/IEC may provide, if 
applicable regulatory authority(ies) permit, expedited re view and approval/favorable 
opi[INVESTIGATOR_51704](s) in ongoing  studies that have the approval /favorable opi[INVESTIGATOR_51705]/IEC.  The investigator will submit all protocol modifications to Genenteach, 
[COMPANY_006] and the regulatory authority(ies) in accordan ce with the governing regulations. Any 
departures from the protoco l must be fully documented in the source documents.   
  
   
 69 REFERENCES:  
 [Bevacizumab references provided as separate document on diskette]  
 
1. Kulke MH, Stuart K, Enzinger P C, et al. Phase II study of temozolomide and 
thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:[ADDRESS_54711] -line chemotherapy with capecitabine 
and temozolomide in patients with met astatic pancreatic endocrine carcinomas. Cancer 
2011;117:268 -75. 
3. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic 
neuroendocrine tumors. The New England journal of medicine 2011;364:514 -23. 
4. Raymond E, Dahan L, Raoul JL, et al. Suniti nib malate for the treatment of 
pancreatic neuroendocrine tu mors. The New England journal of medicine 
2011;364:501 -13. 
5. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is 
effective in treatment of advanced malignant neuroendocrine tumo rs. Clin Cancer Res 
2007;13:[ADDRESS_54712] -line chemotherapy with capecitabine 
and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 
2010.  
7. Kulke MH, Hornick JL, Frauenhoffer C, et a l. O6 -methylguanine DNA 
methyltransferase deficiency and res ponse to temozolomide -based therapy in patients 
with neuroendocrine tumors. Clinical cancer research : an official journal of the 
American Association for Cancer Research 2009;15:338 -45. 
8. Kulke M, Stuart K, Earle C, et al. A phase II study of temozolomid e and 
bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 24: (June 
[ADDRESS_54713]; abstr 4044) 2006.  
9. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth facto r in 
advanced carcinoid tumor: a random assignment phase II study of depot octreotide with 
bevacizumab and pegylated interferon alpha -2b. J Clin Oncol 2008;26:1316 -23. 
10. O'Reilly SM, Newlands ES, Glaser MG, et al. Temozolomide: a new oral 
cytotoxic chemo therapeutic agent with promising activity against primary br ain tumours. 
Eur J Cancer 1993;29A:[ADDRESS_54714] relapse. Temodal Brain Tumor Group. J Clin Oncol  1999;17:2762 -71. 
12. Tentori L, Graziani G, Gilberti S, Lacal PM, Bonmassar E, D'Atri S. Triazene 
compounds induce apoptosis in O6 -alkylguanine -DNA alkyltransferase deficient 
leukemia cell lines.  Leukemia 1995;9:1888 -95. 
13. Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T. Phase I study of 
temozolomide in relapsed/refractory acute leukemia. J Clin Oncol 2002;20:3249 -53. 
14. Brandwein JM, Schimmer AD, Schuh AC, et al. A Phase II Study of 
Temozolomide Therapy for Poor Risk Patients A ge >= 60 Years with Acute Myeloid 
Leukemia (AML) - Low Levels of MGMT May Predict for Response. ASH Annual 
Meeting Abstracts 2005;106:1860 -. 
   
 70 15. Maire F, Hammel P, Faivre S, et al. Temozolomide: a safe and effective 
treatment for malignant digestive endocr ine tumors. Neuroendocrinology 2009;90:67 -
72. 
16. Isacoff W, Moss R, Pecora A, Fine R. Temozolomode/capecitabine therapy for 
metastatic neuroen docrine tumors of the pancreas.  A retrospective review. J Clin Oncol 
24: (June [ADDRESS_54715]; abstr [ZIP_CODE]) 2006.  
17. Pecout S, Baudin E, Paoli A, et al. Efficacy and tolerance of chemotherapy with 
dacarbazine or temozolomide associated or not with 5 -fluorourac il (5-FU) in endocrine 
carcinomas: A retrospective multicentric study from the Groupe des Tumeurs 
Endocrines (GTE ). J Clin Oncol 29 (suppl; abstr e15523) 2009.  
18. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from 
temozolomide in glioblastoma. N Engl J Med 2005;352:997 -1003.  
19. Qian XC, Brent TP. Methylation hot spots in the 5' flanking reg ion denote 
silencing of the O6 -methylguanine -DNA methyltransferase gene. Cancer Res 
1997;57:3672 -7. 
20. Watts GS, Pi[INVESTIGATOR_51706], Costello JF, Peng YM, Dalton WS, Futscher BW. 
Methylation of discrete regions of the O6 -methylguanine DNA methyltransferase 
(MGMT) CpG island is associated with heterochromatinization of the MGMT 
transcription start site and silencing of the gene. Mol Cell Biol 1997;17:[ADDRESS_54716] -line temozolomide 
chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro -Oncolog ia 
(GICNO). J Clin Oncol 2004;22:4779 -86. 
22. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of O6 -alkylguanine -
DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 
2003;88:1004 -11. 
23. Schuller J, Cassidy J, Dumont  E, et al. Preferential activation of capecitabine in 
tumor following oral administration to colorectal cancer pa tients. Cancer chemotherapy 
and pharmacology 2000;45:[ADDRESS_54717] -Bohas C, Chayvialle JA, Pi[INVESTIGATOR_51707] F. 
Perfusion characterization of liver metastases from endocrine tumors: Computed 
tomography perfusion. World J Radiol 2 010;2:[ADDRESS_54718] findings in patients with 
metastatic carcinoid tumors undergoing bevacizu mab and interferon therapy. AJR 
American journal of roentgenology 2011;196:569 -76. 
26. d'Assignies G, Couvelard A , Bahrami S, et al. Pancreatic endocrine tumors: 
tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with 
prognost ic factors. Radiology 2009;250:[ADDRESS_54719]: noninvasive surrogate m arker for 
stratification of pancreatic cancer response to concurrent chemo - and radiation therapy. 
Radiology 2009;250:110 -7. 
28. Klimstra DS, M odlin IR, Coppola D, Lloyd RV, Suster S. The pathologic 
classification of neuroendocrine tumors: a review of nome nclature, grading, and staging 
systems. Pancreas 2010;39:707 -12. 
29. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation crit eria 
in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228 -47. 
   
 71 30. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great 
Vessels. 9th ed. . [LOCATION_011], MA: Little, Brown & Co; 1994.  
31       Jeff  A. Simerville , MD, William C. Maxted, MD, John J. Pahira, MD. Urinalysis: A 
Comprehensive Review  J. Am Fam Ph ysician.  2005  Mar 15;71(6):1153 -1162 . 
32       Carroll MF1, Temte JL . Proteinuria  in adults : a diagnostic  approach. Am Fam 
Physician . 2000 Sep 15;62(6): 1333 -40. 
 
 
 
 
 
 
  
   
 72 APPENDICES:  
Appendix A: NCI Common Toxicity Criteria , v4.0 (websi te provided)  
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-14_QuickReference_5x7.pdf  
 
Appendix B: FDA MedWatch 3500a Form  (website provided)  
http://www.fd a.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm  
 
Appendix C: NYHA Guidelines  (included)  
 
Appendix D: Genentech Safety Reporting Cover Sheet (included)  
 
 
ATTACHMENTS:  
Attachment  1:  Informed Consent  Form (separate attachment)  
 
 
 
  
   
 73 APPENDIX C:  N YHA Guidelines30 
 
Class I  (mild) : no limitation is experienced in any activities; there are no sym ptoms from 
ordinary activities.  
 
Class II  (mild) : slight, mild limitation of activity; the patient is comfortable at rest or with 
mild exertion.  
 
Class III  (moderate) : marked limitation of any activity; the patient is comfortabl e only at 
rest. 
 
Class IV  (severe) : any physical activity brings on discomfort and symptoms occur at 
rest. 
 
  
   
 74 APPENDIX D:  
 
 
 
SAFETY REPORTING FAX COVER SHEET  
Genentech Supported Research  
AE / SAE FAX No : xxxxxxxxxx  
Alternate Fax No: xxxxxxxxxxx  
 
Genentech Study Number   
Principal I nvestigator   
Site Name   
[CONTACT_51770] #   
Reporter Fax #   
 
Initial Report Date  [INSERT investigational product name]  / [INSERT 
investigational product name]  / [INSERT 
investigational product name]  
Follow -up Report Date  [INSERT investigational product name]  / [INSERT 
investigational product name]  / [INSERT 
investigational product name]  
 
Subject Initials  
(Enter a dash if patient has no 
middle name)  [INSERT investigational product name]  - [INSERT 
investigational product name]  - [INSERT 
investigational product name]  
 
SAE or Safety Reporting questions, contact [CONTACT_38319]: ( xxxxxxxxxxx  
PLEASE PLACE MEDWATCH REPORT or SAFETY REPORT BEHIND THIS COVER 
SHEET  
 
